WO2021098745A1 - 一类蛋白受体激酶抑制剂的制备和应用 - Google Patents

一类蛋白受体激酶抑制剂的制备和应用 Download PDF

Info

Publication number
WO2021098745A1
WO2021098745A1 PCT/CN2020/129913 CN2020129913W WO2021098745A1 WO 2021098745 A1 WO2021098745 A1 WO 2021098745A1 CN 2020129913 W CN2020129913 W CN 2020129913W WO 2021098745 A1 WO2021098745 A1 WO 2021098745A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
unsubstituted
group
difluorophenyl
compound
Prior art date
Application number
PCT/CN2020/129913
Other languages
English (en)
French (fr)
Inventor
张淑芸
冯志勇
江磊
金贤
乔智
寿建勇
尚珂
吴淡宜
许灵灵
徐圆
张毅
张宇星
Original Assignee
上海轶诺药业有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海轶诺药业有限公司 filed Critical 上海轶诺药业有限公司
Priority to CN202080074424.6A priority Critical patent/CN114641476B/zh
Publication of WO2021098745A1 publication Critical patent/WO2021098745A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present invention relates to the technical field of medicine, and more specifically, to a protein receptor kinase inhibitor.
  • Tropomyosin-receptor kinase is a type of nerve growth factor receptor, which belongs to the receptor tyrosine kinase family, which mainly includes three members of TRKA, TRKB and TRKC, which are highly homologous. It is encoded by three genes, NTRK1, NTRK2 and NTRK3. These receptor tyrosine kinases are mainly expressed in nervous tissues and play an important role in the development and physiological functions of the nervous system through the activation of neurotrophins (neurotrophins). TRK acts as a tyrosine kinase receptor, and each TRK has its corresponding ligand to bind to and activate its downstream signaling pathways.
  • NGF nerve growth factor
  • TRKB ligands include BDGF (brain-derived growth factor) and NT-4/5 (neurotrophin-4/5); NT-3 specifically binds and activates TRKC . All three TRK receptors contain extracellular domains for ligand binding, transmembrane domains and intracellular domains with kinase activity.
  • TRK signaling pathway is usually precisely regulated, and its abnormal activation is closely related to tumorigenesis. Research results show that there are many mechanisms that cause abnormal activation of the TRK pathway, including gene fusion, protein overexpression, and single nucleotide mutations.
  • NTRK gene fusion has been proven to cause multiple An important factor in tumorigenesis, and does not depend on the tissue source and type of the tumor.
  • NTRK fusion genes have been discovered, such as ETV6-NTRK3, MPRIP-NTRK1, CD74-NTRK1, etc.
  • ETV6-NTRK3, MPRIP-NTRK1, CD74-NTRK1, etc. The results of clinical trials in recent years have shown that these fusion genes are very effective anti-cancer targets, and tumors containing NTRK fusion genes have a very significant response rate to TRK inhibitors.
  • TRK target inhibitors have been reported.
  • some patients undergoing treatment have developed drug resistance, which has been confirmed to be caused by partial base mutations in the enzyme activity region.
  • drug resistance has been confirmed to be caused by partial base mutations in the enzyme activity region.
  • the purpose of the present invention is to provide a new type of TRK kinase inhibitor and its preparation method and application.
  • the first aspect of the present invention provides a compound represented by formula I, or its stereoisomer or racemate, or its pharmaceutically acceptable salt:
  • X 4 and X 5 are each independently N or C;
  • R is selected from the following group: H, C1-C4 alkyl, halogen;
  • L 2 is selected from the following group: substituted or unsubstituted C6-C10 aryl groups, substituted or unsubstituted 5-10 membered heteroaryl groups having 1-3 heteroatoms selected from N, S and O, substituted or unsubstituted Substituted 5-12 membered heterocyclic group (including fused ring, bridged ring and spiro ring) with 1-3 heteroatoms selected from N, S and O;
  • L 1 and L 2 together form a group selected from the group consisting of: substituted or unsubstituted 10-12 membered bicyclic nitrogen-containing heteroaryl, or substituted or unsubstituted 10-12 membered bicyclic nitrogen-containing Heterocyclyl; wherein the heteroaryl or heterocyclic group has 1-3 heteroatoms selected from N, S and O;
  • Rc is a substituted or unsubstituted 4-6 membered heterocyclic group (preferably a saturated or unsaturated nitrogen heterocyclic group), a substituted or unsubstituted 5-10 membered heteroaryl group; wherein, the heteroaryl group Or the heterocyclic group has 1-3 heteroatoms selected from N, S and O;
  • R A is among them
  • X 1 , X 2 , and X 3 are each independently CR 6 or N;
  • R 6 is hydrogen, deuterium, hydroxyl, halogen, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C1-C6 alkoxy base;
  • n 1, 2 or 3;
  • Each R 3 is independently hydrogen, deuterium, hydroxyl, halogen, trifluoromethyl, cyano, amino, amide, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C1-C6 alkoxy base;
  • n is 2 and two R 3 together form -O-(CH 2 ) m -O-; m is an integer of 1-4;
  • R B is a substituted or unsubstituted 4-7 membered heterocyclic ring (the heterocyclic ring contains 1-3 heteroatoms selected from nitrogen atoms, oxygen atoms and sulfur atoms); -(CH 2 ) m1 -, -O- (CH 2 ) m2 -O-; where m1 and m2 are each independently an integer of 1-4;
  • R B is -substituted or unsubstituted -C1-C10 alkylene-X 2- (where X 2 is NH, O, S or S(O) 2 ), substituted or unsubstituted C1-C6 alkyl , Substituted or unsubstituted C1-C6 alkoxy;
  • R A is selected from the group:
  • n is 1, 2 or 3; and R 3 is hydrogen, deuterium, hydroxyl, halogen, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C1-C6 alkoxy; or n 2 and two R 3 together form -O-(CH 2 ) m -O-; m is an integer of 1-4;
  • R 3 , R 4 , and R 5 at other positions are each independently hydrogen, deuterium, hydroxyl, halogen, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C1-C6 alkoxy.
  • R A is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • X 1 is CR 6 or N;
  • X 2 and X 3 are each independently CR 6 ;
  • n 1, 2 or 3; and R 3 is hydrogen, deuterium, hydroxyl, halogen, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C1-C6 alkoxy; or n is 2 and two R 3 together form -O-(CH 2 ) m -O-; m is an integer of 1-4.
  • the compound of formula I has a structure shown in the following formula:
  • said L 1 and L 2 together form a substituted or unsubstituted group selected from the following group:
  • said L 1 and L 2 together form a group selected from the following group:
  • the compound of formula I has a structure shown in the following formula:
  • the compound of formula I has a structure shown in the following formula:
  • the compound is selected from the following group:
  • the second aspect of the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of the compound according to the first aspect of the present invention or its stereoisomer or racemate or its pharmaceutically acceptable salt , And pharmaceutically acceptable excipients.
  • the third aspect of the present invention provides a compound as described in the first aspect of the present invention or a stereoisomer or racemate or a pharmaceutically acceptable salt thereof, or as described in the second aspect of the present invention
  • the use of the pharmaceutical composition for the prevention and treatment of TRK-related diseases.
  • the TRK-related disease is selected from the group consisting of cancer, proliferative disease, pain, skin disease or disease, metabolic disease, muscle disease, neurological disease, autoimmune disease, itching caused by dermatitis, Inflammation-related diseases, bone-related diseases.
  • the cancer is selected from cancers (including but not limited to) related to TRK dysfunction (TRK gene amplification, or overexpression, or mutation, or dysfunction activation caused by gene fusion): neuroma Cell tumor, prostate cancer, thyroid cancer, lung cancer, ovarian cancer, pancreatic cancer, colorectal cancer, non-small cell lung cancer, fibrosarcoma, etc.
  • TRK dysfunction TRK gene amplification, or overexpression, or mutation, or dysfunction activation caused by gene fusion
  • the fourth aspect of the present invention provides a compound as described in the first aspect of the present invention or a stereoisomer or tautomer, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or
  • the use of the pharmaceutical composition according to the second aspect of the present invention is used for the preparation of prevention and/or treatment and TRK dysfunction (TRK gene amplification, or overexpression, or mutation, or dysfunction activation caused by gene fusion) Pharmaceutical composition for related diseases.
  • the pharmaceutical composition can be used in combination with other therapeutic agents.
  • the drug combination includes, but is not limited to, other target kinase inhibitors, immunomodulators (tumor immune checkpoint inhibitors), cell division blockers, and other conventional first-line chemotherapy drugs.
  • the disease is selected from the following group: cancer, proliferative disease, pain, skin disease or disease, metabolic disease, muscle disease, neurological disease, autoimmune disease, itching caused by dermatitis.
  • the cancer is selected from cancers (including but not limited to) related to TRK dysfunction (TRK gene amplification, or overexpression, or mutation, or dysfunction activation caused by gene fusion): neuroma Cell tumor, prostate cancer, thyroid cancer, lung cancer, ovarian cancer, pancreatic cancer, colorectal cancer, non-small cell lung cancer, fibrosarcoma, etc.
  • TRK dysfunction TRK gene amplification, or overexpression, or mutation, or dysfunction activation caused by gene fusion
  • the fifth aspect of the present invention provides a TRK inhibitor, the inhibitor comprising the compound as described in the first aspect of the present invention, or its stereoisomer or tautomer, or its pharmaceutically acceptable The salt, hydrate or solvate.
  • the TRK inhibitor selectively inhibits one or more TRK kinases selected from the following group: TRKA, TRKB or TRKC.
  • Figure 1 shows the inhibition rate of TRKA phosphorylation level after administration of the compound of the present invention
  • Figure 2 shows the change in tumor volume of mice after administration of the compound of the present invention.
  • the term “comprising” or “including (including)” can be open, semi-closed, and closed. In other words, the term also includes “essentially composed of” or “consisting of”.
  • alkyl refers to a fully saturated linear or branched hydrocarbon chain group consisting of only carbon atoms and hydrogen atoms, having, for example, 1 to 12 (Preferably 1 to 8, more preferably 1 to 6) carbon atoms, and are connected to the rest of the molecule through a single bond, such as but not limited to methyl, ethyl, n-propyl, isopropyl, N-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, 2,2-dimethylpropyl, n-hexyl, heptyl, 2-methylhexyl, 3 -Methylhexyl, octyl, nonyl and decyl, etc.
  • C1-C6 alkyl refers to an alkyl group containing 1
  • 6-10 membered aromatic ring means an aromatic ring having 6-10 ring atoms, and the ring atoms are carbon atoms.
  • the aromatic ring may be monocyclic or bicyclic.
  • benzene ring, naphthalene ring and similar groups are examples of aromatic ring having 6-10 ring atoms, and the ring atoms are carbon atoms.
  • the term "5-10 membered heteroaromatic ring” means a heteroaromatic ring with 5-10 ring atoms, and the ring atom has at least 1 (may (1, 2, or 3) are heteroatoms selected from nitrogen, oxygen and sulfur.
  • the heteroaromatic ring may be monocyclic or bicyclic.
  • the compound of the present invention is a compound represented by formula I or a stereoisomer or racemate or a pharmaceutically acceptable salt thereof.
  • the compounds of the present invention may contain one or more chiral carbon atoms, and therefore can produce enantiomers, diastereomers and other stereoisomeric forms.
  • Each chiral carbon atom can be defined as (R)- or (S)- based on stereochemistry.
  • the present invention is intended to include all possible isomers, as well as their racemates and optically pure forms.
  • racemates, diastereomers or enantiomers can be selected as raw materials or intermediates.
  • Optically active isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, such as crystallization and chiral chromatography.
  • pharmaceutically acceptable salt includes pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
  • “Pharmaceutically acceptable acid addition salt” refers to a salt formed with an inorganic acid or an organic acid that can retain the biological effectiveness of the free base without other side effects.
  • Inorganic acid salts include, but are not limited to, hydrochloride, hydrobromide, sulfate, nitrate, phosphate, etc.
  • organic acid salts include, but are not limited to, formate, acetate, and 2,2-dichloroacetate , Trifluoroacetate, propionate, caproate, caprylate, caprate, undecylenate, glycolate, gluconate, lactate, sebacate, hexanoate Acid salt, glutarate, malonate, oxalate, maleate, succinate, fumarate, tartrate, citrate, palmitate, stearate, oleate , Cinnamate, laurate, malate, glutamate, pyroglutamate, aspartate, benzoate, methanesulfonate,
  • “Pharmaceutically acceptable base addition salt” refers to a salt formed with an inorganic base or an organic base that can maintain the biological effectiveness of the free acid without other side effects.
  • Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like.
  • Preferred inorganic salts are ammonium, sodium, potassium, calcium and magnesium salts.
  • Salts derived from organic bases include but are not limited to the following salts: primary amines, secondary amines and tertiary amines, substituted amines, including natural substituted amines, cyclic amines and basic ion exchange resins , Such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, triethanolamine, dimethylethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, bicyclic Hexylamine, lysine, arginine, histidine, caffeine, procaine, choline, betaine, ethylenediamine, glucosamine, methylglucosamine, theobromine, purine, piperazine, piperazine Pyridine, N-ethylpiperidine, polyamine resin, etc.
  • Preferred organic bases include isopropylamine, diethylamine, ethanolamine, trimethyl
  • reaction scheme exemplarily illustrates the method for preparing the compound represented by formula I or its stereoisomer or racemate or its pharmaceutically acceptable salt, wherein each group is as described above. It should be understood that in the following reaction schemes, combinations of substituents and/or variables in the general formulae are permissible only when such combinations result in stable compounds. It should also be understood that other general formulas can be prepared by those skilled in the field of organic chemistry by the methods disclosed herein (by applying appropriately substituted starting materials and modifying synthesis parameters as required by methods known to those skilled in the art) or known methods.
  • the method includes the steps:
  • the method includes the steps:
  • the above method may further include the step of modifying the compound, and the substituent may also be prepared by selecting the corresponding starting material.
  • this step also includes a step of deprotecting the protecting group.
  • a protecting group for example, an amino protecting group or a hydroxy protecting group, etc.
  • the compound of the present invention has excellent TRK (such as TRKA, TRKB, TRKC) inhibitory activity, therefore the compound of the present invention and its various crystal forms, pharmaceutically acceptable inorganic or organic salts, hydrates or solvates, and containing the
  • TRK such as TRKA, TRKB, TRKC
  • the pharmaceutical composition in which the compound of the invention is the main active ingredient can be used to prevent and/or treat diseases related to the activity or expression of TRK kinase (for example, cancer).
  • the term "pharmaceutical composition” refers to a preparation of the compound of the present invention and a medium generally accepted in the art for the delivery of a biologically active compound to a mammal (such as a human).
  • the medium includes a pharmaceutically acceptable carrier.
  • the purpose of the pharmaceutical composition is to promote the administration of the organism, facilitate the absorption of the active ingredients and then exert the biological activity.
  • the term "pharmaceutically acceptable” refers to a substance (such as a carrier or diluent) that does not affect the biological activity or properties of the compound of the present invention, and is relatively non-toxic, that is, the substance can be administered to an individual without causing Undesirable biological reactions or interactions with any components contained in the composition in an undesirable manner.
  • the term "pharmaceutically acceptable excipient” includes, but is not limited to, any adjuvant, carrier, excipient, glidant, Sweeteners, diluents, preservatives, dyes/colorants, flavors, surfactants, wetting agents, dispersants, suspending agents, stabilizers, isotonic agents, solvents or emulsifiers.
  • tumor includes but is not limited to glioma, sarcoma, melanoma, articular chondroma, cholangiomas, leukemia, gastrointestinal stromal tumor, histocytic lymphoma, non-small cell lung cancer, small Cell lung cancer, pancreatic cancer, lung squamous cell carcinoma, lung adenocarcinoma, breast cancer, prostate cancer, liver cancer, skin cancer, epithelial cell cancer, cervical cancer, ovarian cancer, bowel cancer, nasopharyngeal cancer, brain cancer, bone cancer, esophageal cancer , Melanoma, kidney cancer, oral cancer and other diseases.
  • prevention includes reducing the likelihood of the occurrence or exacerbation of a disease or condition in a patient.
  • treatment and other similar synonyms include the following meanings:
  • the terms "effective amount”, “therapeutically effective amount” or “pharmaceutical effective amount” refer to at least one agent that is sufficient to relieve one or more symptoms of the disease or condition being treated after administration Or the amount of compound. The result can be a reduction and/or alleviation of signs, symptoms or causes, or any other desired changes in the biological system.
  • the "effective amount” for treatment is the amount of the composition containing the compound disclosed herein that is required to provide significant disease relief clinically. Techniques such as dose escalation tests can be used to determine the effective amount suitable for any individual case.
  • the terms “administration”, “administration”, “administration”, etc. refer to methods capable of delivering a compound or composition to a desired site for biological action. These methods include, but are not limited to, oral route, transduodenal route, parenteral injection (including intravenous, subcutaneous, intraperitoneal, intramuscular, intraarterial injection or infusion), topical administration, and rectal administration.
  • parenteral injection including intravenous, subcutaneous, intraperitoneal, intramuscular, intraarterial injection or infusion
  • topical administration and rectal administration.
  • Those skilled in the art are familiar with the application techniques that can be used for the compounds and methods described herein, for example in Goodman and Gilman, The Pharmaceutical Basis of Therapeutics, current ed.; Pergamon; and Remington's, Pharmaceuticals (current edition), Mack Publishing Co., Those discussed in Easton, Pa.
  • the compounds and compositions discussed herein are administered orally.
  • drug combination refers to drugs obtained by mixing or combining more than one active ingredient Treatment, which includes fixed and non-fixed combinations of active ingredients.
  • fixed combination refers to the simultaneous administration of at least one compound described herein and at least one synergistic agent to a patient in the form of a single entity or a single dosage form.
  • non-fixed combination refers to the simultaneous administration, combination or sequential administration of at least one compound described herein and at least one synergistic agent to a patient in the form of separate entities. These also apply to cocktail therapy, such as the administration of three or more active ingredients.
  • the compound of the present invention has excellent pharmacokinetic properties.
  • the compound of the present invention can effectively inhibit tumor growth in tumor-bearing mice.
  • the compound of the present invention can effectively inhibit the proliferation of KM12-LUC cells.
  • the compound of the present invention can effectively inhibit the phosphorylation level of TRKA, TRKB and TRKC at the cytological level.
  • the functional group of the intermediate compound may need to be protected by an appropriate protecting group.
  • Such functional groups include hydroxyl, amino, mercapto and carboxylic acid.
  • Suitable hydroxy protecting groups include trialkylsilyl or diarylalkylsilyl (e.g. tert-butyldimethylsilyl, tert-butyldiphenylsilyl or trimethylsilyl) , Tetrahydropyranyl, benzyl, etc.
  • Suitable protecting groups for amino, amidino and guanidino include tert-butoxycarbonyl, benzyloxycarbonyl and the like.
  • Suitable sulfhydryl protecting groups include -C(O)-R" (wherein R" is alkyl, aryl or aralkyl), p-methoxybenzyl, trityl and the like.
  • Suitable carboxy protecting groups include alkyl, aryl or aralkyl esters.
  • Protecting groups can be introduced and removed according to standard techniques known to those skilled in the art and as described herein. The use of protective groups is detailed in Greene, T.W. and P.G.M. Wuts, Protective Groups in Organi Synthesis, (1999), 4th Ed., Wiley.
  • the protecting group can also be a polymer resin.
  • reaction was stirred at room temperature for 1 hour and then concentrated, then diluted with dichloromethane (50mL) and water (5mL), washed with saturated sodium bicarbonate aqueous solution (50mL*1), saturated sodium chloride aqueous solution (50mL*1).
  • reaction solution was cooled to room temperature and diluted with ethyl acetate.
  • organic phase was washed with water and salt and then concentrated.
  • TRKA, TRKB, and TRKC proteins were purchased from Carna Biosciences.
  • HTRF kinEASE TK kit was purchased from CisbioBioassays. Use BioTek microplate reader Synergy Neo 2 to read the plate.
  • test compound was diluted by a 3-fold concentration gradient, and the final concentration was from 1 ⁇ M to 0.05 nM. Ten concentrations, each with two replicate wells; the content of DMSO in the detection reaction was 1%.
  • TRKA protein kinase 1 ⁇ M TK Substrate-biotin peptide substrate, 14.68 ⁇ M ATP, 1 ⁇ enzymatic buffer, 5mM MgCl 2 , 1mM DTT.
  • the detection plate is White Proxiplate384-Plus plate (PerkinElmer), reacted at room temperature for 40 minutes, and the reaction system is 10 ⁇ l.
  • TRKB protein kinase 1 ⁇ M TK Substrate-biotin peptide substrate, 4.77 ⁇ M ATP, 1 ⁇ enzymatic buffer, 5mM MgCl 2 , 1mMMnCl 2 , 1mM DTT.
  • the detection plate is White Proxiplate 384-Plus plate (PerkinElmer), reacted at room temperature for 50 minutes, and the reaction system is 10 ⁇ l.
  • TRKC protein kinase 1 ⁇ M TK Substrate-biotin peptide substrate, 25.64 ⁇ M ATP, 1 ⁇ enzymatic buffer, 5mM MgCl 2 , 1mM DTT.
  • the detection plate is White Proxiplate 384-Plus plate (PerkinElmer), reacted at room temperature for 40 minutes, and the reaction system is 10 ⁇ l.
  • Ratio max is a positive control without test compound
  • Ratio test is the test value of each concentration of different compounds. 4 parameter curve fitting measured IC50 (nM) data, see Table 1 for details.
  • Example 14 ⁇ 10 ⁇ 10 ⁇ 10
  • Example 15 ⁇ 10 ⁇ 10 ⁇ 10
  • Example 16 ⁇ 10 ⁇ 10 ⁇ 10
  • Example 17 ⁇ 10 ⁇ 10 ⁇ 10
  • Example 18 ⁇ 10 ⁇ 10 ⁇ 10
  • the human colon cancer cell line KM12-LUC (LUC, stably expressing Luciferace) containing the TPM3-NTRK1 fusion gene was used as a model for evaluating the cytological level of the test compound.
  • the TRK fusion gene in KM12-LUC cells makes it independent of the stimulation of extracellular growth factors, and can continue to spontaneously activate and activate its downstream signal pathways MAPK-ERK, PI3K-AKT and other signal pathways closely related to cell proliferation. Therefore, inhibiting TRK activity in KM12-LUC cells can significantly inhibit cell proliferation.
  • the method is as follows: on the first day, inoculate the cells in a 384-well plate, 2000 cells/well; on the second day, add different concentrations of the test compound; on the fifth day, add CellTiter-Glo (Promega) to detect cell viability and calculate the cells for 72 hours Proliferation inhibition rate. Use prism5 to perform statistical analysis and obtain the IC 50 value of the test compound.
  • TRKA Recombinant human TRKA (G595R), TRKA (G667C), and TRKC (G623R) proteins were purchased from SignalChem.
  • HTRF kinEASE TK kit was purchased from CisbioBioassays. Use BioTek microplate reader Synergy Neo 2 to read the plate.
  • test compound was diluted in a 4-fold concentration gradient, and the final concentration was 1 ⁇ M to 0.004 nM, 10 concentrations, each with two replicate wells; the content of DMSO in the detection reaction was 1%.
  • TRKA TRKA (G595R) protein kinase
  • 1 ⁇ M TK Substrate-biotin peptide substrate
  • 4.5 ⁇ M ATP 1 ⁇ enzymatic buffer
  • 5mM MgCl 2 1mM DTT.
  • the detection plate is White Proxiplate384-Plus plate (PerkinElmer), the reaction is at room temperature for 30 minutes, and the reaction system is 10 ⁇ l.
  • TRKA(G667C) protein kinase 0.026ng/ ⁇ l TRKA(G667C) protein kinase, 1 ⁇ M TK Substrate-biotin peptide substrate, 5.5 ⁇ M ATP, 1 ⁇ enzymatic buffer, 5mM MgCl 2 , 1mM DTT.
  • the detection plate is White Proxiplate 384-Plus plate (PerkinElmer), and the reaction system is 10 ⁇ l at room temperature for 30 minutes.
  • the NIH-3T3 cell line stably expressing ⁇ TRKA or ⁇ TRKA (G595R) was constructed by plasmid transfection.
  • the results show that the compound of the present invention can effectively inhibit the phosphorylation level of TRKA in ⁇ TRKA/NIH-3T3 cells or ⁇ TRKA(G595R)/NIH-3T3 cells at the cytological level.
  • Example 10 ⁇ 10
  • Example 11 ⁇ 10
  • ⁇ TRKA(G595R)/3T3 cells (5 ⁇ 10 6 ) were injected subcutaneously into the dorsal area of the mouse.
  • the tumor volume was monitored by measuring the diameter with a caliper, and calculated by the following formula: length ⁇ (width2)/2.
  • mice are randomly selected to receive the blank preparation, 3 mg/kg or 30 mg/kg/dose of the test compound.
  • the test compound was administered by oral administration for 7 days, and tumor growth and body weight were monitored daily. Two hours after the last dose, tumor tissue and blood were collected.
  • Figure 1 shows the phosphorylation level of TRKA in tumor samples after administration of the compound of Example 1.
  • Figure 2 shows the change in tumor volume of mice after administration of the compound of Example 1. The results show that tumor growth is significantly inhibited after administration of the compound of the present invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明提供了一种蛋白受体激酶抑制剂的制备方法。具体地，本发明公开了一种式I所示的化合物或其立体异构体或外消旋体或其药学上可接受的盐，其中，各基团的定义如说明书中所述。本发明还公开了上述化合物作为TRK激酶抑制剂的用途。

Description

一类蛋白受体激酶抑制剂的制备和应用 技术领域
本发明涉及医药技术领域，更具体而言，涉及一种蛋白受体激酶抑制剂。
背景技术
原肌球蛋白受体激酶(tropomyosin-receptor kinase,TRK)是一类神经生长因子受体，隶属于受体酪氨酸激酶家族，主要包括高度同源的TRKA、TRKB和TRKC三个成员，分别由NTRK1、NTRK2和NTRK3三个基因编码而成。这些受体酪氨酸激酶主要在神经组织中表达，并通过神经营养因子NTs(neurotrophins)的激活在神经系统的发育和生理功能中发挥重要作用。TRK作为酪氨酸激酶受体，每个TRK都有与其相对应的配体结合并激活其下游的信号通路。NGF(nerve growth factor)特异性结合并激活TRKA；TRKB的配体包括有BDGF(brain-derived growth factor)和NT-4/5(neurotrophin-4/5)；NT-3特异性结合并激活TRKC。三种TRK受体均含有用于配体结合的细胞外结构域、跨膜结构域和具有激酶活性的胞内结构域。
当特定配体与相应受体的胞外结构域相结合，会引发受体的寡聚化和胞质内激酶结构域中特定酪氨酸残基的磷酸化，从而引起下游信号通路如Ras/MAPK、PLCγ/PKC和PI3K/AKT信号通路的激活，进而调控神经细胞的增殖、分化和存活等一系列生理过程。TRK信号通路通常被精确调控，而它的异常激活则与肿瘤发生密切相关。研究结果表明，引起TRK通路异常激活的机制有很多，包括基因融合、蛋白质过度表达和单核苷酸突变，这些异常与肿瘤的发病机制密切相关，特别是NTRK基因融合已被证实是导致多种肿瘤发生的重要因素，且不依赖于肿瘤的组织来源和类型。在当前二代测序技术和精准医疗的迅猛发展下，越来越多的NTRK融合基因被发现，例如ETV6-NTRK3、MPRIP–NTRK1、CD74–NTRK1等。近年来的临床试验结果表明，这些融合基因是非常有效的抗癌靶点，且含有NTRK融合基因的肿瘤对TRK抑制剂有非常显著的响应率。
因此，越来越多的TRK靶点抑制剂被报道，同时，在临床试验阶段，已经发现有部分接受治疗的患者出现了耐药现象，并被证实是由酶活区域的部分碱基突变引起，例如NTRK1 G595R或G667C突变，NTRK3的G623R或G696A突变。因此，本领域仍然需要开发新一代TRK激酶抑制剂，以解决上述问题。
发明内容
本发明的目的在于提供一类新的TRK激酶抑制剂及其制备方法和用途。
本发明第一方面，提供了一种式I所示的化合物，或其立体异构体或外消旋体，或其药学上可接受的盐：
Figure PCTCN2020129913-appb-000001
其中，
X 4和X 5各自独立地为N或C；
L 1选自下组：-NH-、-CH＝CH-、-NH(CHR)-、-NHC(O)NH-、-CH 2-O-、-CH 2-S-、-NHS(O) 2-、-S(O) 2-、-S(O)-；R选自下组：H、C1-C4烷基、卤素；
L 2选自下组：取代或未取代的C6-C10芳基、取代或未取代的具有1-3个选自N、S和O的杂原子的5-10元杂芳基、取代或未取代的具有1-3个选自N、S和O的杂原子的5-12元杂环基(包括并环、桥环、螺环)；
或所述的L 1和L 2共同形成选自下组的基团：取代或未取代的10-12元二环含氮杂芳基，或取代或未取代的10-12元二环含氮杂环基；其中，所述的杂芳基或杂环基具有1-3个选自N、S和O的杂原子；
Rc为取代或未取代的4-6元的杂环基(优选为饱和或不饱和的氮杂环基)、取代或未取代的5-10元杂芳基；其中，所述的杂芳基或杂环基具有1-3个选自N、S和O的杂原子；
R A为
Figure PCTCN2020129913-appb-000002
其中，
X 1、X 2、X 3各自独立地为CR 6或N；R 6为氢、氘、羟基、卤素、取代或未取代的C1-C6烷基、或取代或未取代的C1-C6烷氧基；
n为1、2或3；
各个R 3各自独立地为氢、氘、羟基、卤素、三氟甲基，氰基，氨基，酰胺基，取代或未取代的C1-C6烷基、或取代或未取代的C1-C6烷氧基；
或者n为2且两个R 3共同形成-O-(CH 2) m-O-；m为1-4的整数；
R B为取代或未取代的4-7元杂环(所述杂环含有1-3个选自氮原子、氧原子和硫原子的杂原子)；-(CH 2) m1-、-O-(CH 2) m2-O-；其中，m1、m2各自独立地为1-4的整数；
或者R B为-取代或未取代的-C1-C10亚烷基-X 2-(其中，X 2为NH、O、S或S(O) 2)、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基；
除非特别说明，所述的“取代”是指被选自下组的一个或多个(例如2个、3个、4个等)取代基所取代：氘、卤素、卤代的C1-C6烷基、卤代的C1-C6烷氧基、卤代的C3-C8环烷基、甲基砜基、-S(＝O) 2NH 2、氧代(＝O)、-CN、羟基、-NH 2、羧基、C1-C6酰胺基(-C(＝O)-N(R d) 2或-NH-C(＝O)(R d)，R d为H或C1-C5的烷基)、C1-C6烷基-(C1-C6酰胺基)、
Figure PCTCN2020129913-appb-000003
或取代或未取代的选自下组的基团：C1-C6烷基、C1-C6烷氧基、C3-C8环烷基、C1-C6胺基、C6-C10芳基、具有1-3个选自N、S和O的杂原子的5-10元杂芳基、具有1-3个选自N、S和O的杂原子的3-12元杂环基、-(CH 2)-C6-C10芳基、-(CH 2)-(具有1-3个选自N、S和O的杂原子的5-10元杂芳基)，且所述的取代基选自下组：卤素、C1-C6烷基、C1-C6烷氧基、氧代、-CN、-NH 2、-OH、C6-C10芳基、C1-C6胺基、-S(＝O) 2CH 3、-S(＝O) 2NH 2、具有1-3个选自N、S和O的杂原子的5-10元杂芳基；
虚线表示化学键或无。
在另一优选例中，所述的Rc为未取代的，或者被选自下组的一个或多个取代基取代：甲基砜基、-S(＝O) 2NH 2、氧代(＝O)、-CN、羟基、-NH 2、羧基、C1-C6酰胺基(-C(＝O)-N(R d) 2或-NH-C(＝O)(R d)，R d为H或C1-C5的烷基)、C1-C6烷基-(C1-C6酰胺基)、
Figure PCTCN2020129913-appb-000004
或取代或未取代的选自下组的基团：C1-C6烷基、C3-C8环烷基、C1-C6胺基、C6-C10芳基、具有1-3个选自N、S和O的杂原子的5-10元杂芳基、具有1-3个选自N、S和O的杂原子的3-6元杂环基，且所述的取代基选自下组：卤素、C1-C6烷基、C1-C6烷氧基、氧代、-CN、-NH 2、-OH、-S(＝O) 2CH 3。
在另一优选例中，L 1为-CH＝CH-。
在另一优选例中，R A选自下组：
Figure PCTCN2020129913-appb-000005
各式中，X 1、X 2定义同前；
芳香环上，n为1、2或3；且R 3为氢、氘、羟基、卤素、取代或未取代的C1-C6烷基、或取代或未取代的C1-C6烷氧基；或者n为2且两个R 3共同形成-O-(CH 2) m-O-；m为1-4的整数；
其它位置的R 3、R 4、R 5各自独立地为氢、氘、羟基、卤素、取代或未取代的C1-C6烷基、或取代或未取代的C1-C6烷氧基。
在另一优选例中，R A为
Figure PCTCN2020129913-appb-000006
其中，X 1为CR 6或N；X 2、X 3各自独立地为CR 6；
n为1、2或3；且R 3为氢、氘、羟基、卤素、取代或未取代的C1-C6烷基、或取代或未取代的C1-C6烷氧基；或者n为2且两个R 3共同形成-O-(CH 2) m-O-；m为1-4 的整数。
在另一优选例中，所述的式I化合物具有如下式所示的结构：
Figure PCTCN2020129913-appb-000007
在另一优选例中，所述的L 1和L 2共同形成选自下组的取代或未取代的基团：
Figure PCTCN2020129913-appb-000008
在另一优选例中，所述的L 1和L 2共同形成选自下组的基团：
Figure PCTCN2020129913-appb-000009
在另一优选例中，所述的式I化合物具有如下式所示的结构：
Figure PCTCN2020129913-appb-000010
在另一优选例中，所述的式I化合物具有如下式所示的结构：
Figure PCTCN2020129913-appb-000011
在另一优选例中，所述的化合物选自下组：
Figure PCTCN2020129913-appb-000012
Figure PCTCN2020129913-appb-000013
Figure PCTCN2020129913-appb-000014
Figure PCTCN2020129913-appb-000015
Figure PCTCN2020129913-appb-000016
Figure PCTCN2020129913-appb-000017
本发明的第二方面，提供了一种药物组合物，其包含治疗有效量的如本发明第一方面所述的化合物或其立体异构体或外消旋体或其药学上可接受的盐，以及药学上可接受的赋形剂。
本发明的第三方面，提供了一种如本发明第一方面所述的化合物或其立体异构体或外消旋体或其药学上可接受的盐，或如本发明第二方面所述的药物组合物的用途，其用于预防和治疗与TRK相关的疾病的药物中的用途。
在另一优选例中，所述TRK相关的疾病选自下组：癌症，增生性疾病，疼痛，皮肤病或病症，代谢疾病，肌肉疾病，神经性疾病，自身免疫疾病，皮炎引起的瘙痒，炎症相关疾病，骨相关的疾病。
在另一优选例中，所述的癌症选自TRK功能异常(TRK基因扩增、或者过表达、或者突变、或者基因融合导致的功能异常激活)相关的癌症(包括但不仅限于)：神经母细胞瘤，前列腺癌，甲状腺癌，肺癌卵巢癌，胰腺癌、结直肠癌症、非小细胞肺癌、纤维肉瘤等。
本发明的第四方面，提供了一种如本发明第一方面所述的化合物或其立体异构体或互变异构体，或其药学上可接受的盐、水合物或溶剂化物，或如本发明第二方面所述的药物组合物的用途，其用于制备预防和/或治疗与TRK功能异常(TRK基因扩增、或者过表达、或者突变、或者基因融合导致的功能异常激活)相关的疾病的药物组合物。
在另一优选例中，所述的药物组合物可以与其他治疗剂进行联合用药。
在另一优选例中，所述的药物组合包括但不仅限于其他靶点的激酶抑制剂、免疫调节剂(肿瘤免疫检查点抑制剂)、细胞分裂阻滞剂等常规一线化疗药物。
在另一优选例中，所述的疾病选自下组：癌症，增生性疾病，疼痛，皮肤病或病症，代谢疾病，肌肉疾病，神经性疾病，自身免疫疾病，皮炎引起的瘙痒。
在另一优选例中，所述的癌症选自TRK功能异常(TRK基因扩增、或者过表达、或者突变、或者基因融合导致的功能异常激活)相关的癌症(包括但不仅限于)：神经母细胞瘤，前列腺癌，甲状腺癌，肺癌卵巢癌，胰腺癌、结直肠癌症、非小细胞肺癌、纤维肉瘤等。
本发明的第五方面，提供了一种TRK抑制剂，所述抑制剂包含如本发明第一方面所述的化合物、或其立体异构体或互变异构体、或其药学上可接受的盐、水合物或溶剂化物。
在另一优选例中，所述的TRK抑制剂选择性抑制选自下组的一种或多种TRK激酶：TRKA、TRKB或TRKC。
应理解，在本发明范围内中，本发明的上述各技术特征和在下文(如实施例)中具体描述的各技术特征之间都可以互相组合，从而构成新的或优选的技术方案。限于篇幅，在此不再一一累述。
附图说明
图1显示了本发明化合物给药后的TRKA磷酸化水平抑制率情况；
图2显示了本发明化合物给药后小鼠的肿瘤体积变化。
具体实施方式
本发明人通过广泛而深入的研究，首次发现了一类新颖、有效的TRK激酶小分子抑制剂。在此基础上完成了本发明。
术语
除非另外定义，否则本文中所用的全部技术与科学术语均具有如本发明所属领域的普通技术人员通常理解的相同含义。
如本文所用，术语“含有”或“包括(包含)”可以是开放式、半封闭式和封闭式的。换言之，所述术语也包括“基本上由…构成”、或“由…构成”。
在本申请中，作为基团或是其它基团的一部分，术语“烷基”是指完全饱和的直链或支链的烃链基，仅由碳原子和氢原子组成、具有例如1至12个(优选为1至8个，更优选为1至6个)碳原子，且通过单键与分子的其余部分连接，例如包括但不限于甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基、叔丁基、正戊基、2-甲基丁基、2,2-二甲基丙基、正己基、庚基、2-甲基己基、3-甲基己基、辛基、壬基和癸基等。就本发明而言，术语“C1-C6烷基”指含有1至6个碳原子的烷基。
在本申请中，作为基团或是其它基团的一部分，术语“6-10元芳环”意指具有6-10个环原子的芳环，所述环原子为碳原子。所述芳环可以单环或双环。例如苯环、萘环等类似基团。
在本申请中，作为基团或是其它基团的一部分，术语“5-10元杂芳环”意指具有5-10个环原子的杂芳环，所述环原子至少有1个(可以是1个、2个或3个)是选自氮、氧和硫的杂原子。所述杂芳环可以单环或双环。例如，嘧啶并吡唑环、吡嗪并咪唑环、吡啶并吡唑环、吡啶并咪唑环、吡啶并嘧啶环、吡啶并吡啶环。
本发明化合物
本发明的化合物为式I所示化合物或其立体异构体或外消旋体或其药学上可接受的盐。
本发明的化合物可能含有一个或多个手性碳原子，因此可产生对映异构体、非对映异构体及其它立体异构形式。每个手性碳原子可以基于立体化学而被定义为(R)-或 (S)-。本发明旨在包括所有可能的异构体，以及其外消旋体和光学纯形式。本发明的化合物的制备可以选择外消旋体、非对映异构体或对映异构体作为原料或中间体。光学活性的异构体可以使用手性合成子或手性试剂来制备，或者使用常规技术进行拆分，例如采用结晶以及手性色谱等方法。
制备/分离个别异构体的常规技术包括由合适的光学纯前体的手性合成，或者使用例如手性高效液相色谱法拆分外消旋体(或盐或衍生物的外消旋体)，例如可参见Gerald Gübitz and Martin G.Schmid(Eds.),Chiral Separations,Methods and Protocols,Methods in Molecular Biology,Vol.243,2004；A.M.Stalcup,Chiral Separations,Annu.Rev.Anal.Chem.3:341-63,2010；Fumiss et al.(eds.),VOGEL’S ENCYCLOPEDIA OF PRACTICAL ORGANIC CHEMISTRY 5.sup.TH ED.,Longman Scientific and Technical Ltd.,Essex,1991,809-816；Heller,Acc.Chem.Res.1990,23,128。
术语“药学上可接受的盐”包括药学上可接受的酸加成盐和药学上可接受的碱加成盐。
“药学上可接受的酸加成盐”是指能够保留游离碱的生物有效性而无其它副作用的，与无机酸或有机酸所形成的盐。无机酸盐包括但不限于盐酸盐、氢溴酸盐、硫酸盐、硝酸盐、磷酸盐等；有机酸盐包括但不限于甲酸盐、乙酸盐、2,2-二氯乙酸盐、三氟乙酸盐、丙酸盐、己酸盐、辛酸盐、癸酸盐、十一碳烯酸盐、乙醇酸盐、葡糖酸盐、乳酸盐、癸二酸盐、己二酸盐、戊二酸盐、丙二酸盐、草酸盐、马来酸盐、琥珀酸盐、富马酸盐、酒石酸盐、柠檬酸盐、棕榈酸盐、硬脂酸盐、油酸盐、肉桂酸盐、月桂酸盐、苹果酸盐、谷氨酸盐、焦谷氨酸盐、天冬氨酸盐、苯甲酸盐、甲磺酸盐、苯磺酸盐、对甲苯磺酸盐、海藻酸盐、抗坏血酸盐、水杨酸盐、4-氨基水杨酸盐、萘二磺酸盐等。这些盐可通过本专业已知的方法制备。
“药学上可接受的碱加成盐”是指能够保持游离酸的生物有效性而无其它副作用的、与无机碱或有机碱所形成的盐。衍生自无机碱的盐包括但不限于钠盐、钾盐、锂盐、铵盐、钙盐、镁盐、铁盐、锌盐、铜盐、锰盐、铝盐等。优选的无机盐为铵盐、钠盐、钾盐、钙盐及镁盐。衍生自有机碱的盐包括但不限于以下的盐：伯胺类、仲胺类及叔胺类，被取代的胺类，包括天然的被取代胺类、环状胺类及碱性离子交换树脂，例如氨、异丙胺、三甲胺、二乙胺、三乙胺、三丙胺、乙醇胺、二乙醇胺、三乙醇胺、二甲基乙醇胺、2-二甲氨基乙醇、2-二乙氨基乙醇、二环己胺、赖氨酸、精氨酸、组氨酸、咖啡因、普鲁卡因、胆碱、甜菜碱、乙二胺、葡萄糖胺、甲基葡萄糖胺、可可碱、嘌呤、哌嗪、哌啶、N-乙基哌啶、聚胺树脂等。优选的有机碱包括异丙胺、二乙胺、乙醇胺、三甲胺、二环己基胺、胆碱及咖啡因。这些盐可通过本专业已知的方法制备。
制备方法
下列反应方案示例性的说明了制备式I所示化合物或其立体异构体或外消旋体或其药学上可接受的盐的方法，其中各基团均如在上所述。应理解在下列反应方案中，所述通式中取代基和/或变量的组合只有在这类组合导致稳定的化合物时才是可允许的。还应理解其他的通式可由有机化学领域的技术人员通过本文公开的方法(通过应用适当 取代的起始材料并利用本领域技术人员公知的方法根据需要修改合成参数)或已知方法进行制备。
当L1为-CH＝CH-时，所述方法包括步骤：
Figure PCTCN2020129913-appb-000018
当L1为-NH(CHR)-时，所述方法包括步骤：
Figure PCTCN2020129913-appb-000019
其他化合物可以通过替换相应的原料片段，根据本领域通用方法制备。
当本发明的各个化合物具有取代基时，上述的方法还可以包括对于化合物进行取代基修饰的步骤，所述的取代基也可以通过选择对应的起始原料从而制备得到。在本发明公开了骨架结构的构建方法后，这样的修饰是显而易见的。
在另一优选例中，当化合物中还含有保护基团(例如，氨基保护基或羟基保护基等)，则该步骤中还含有脱保护基的步骤。
应用
本发明的化合物具有优异的TRK(例如TRKA、TRKB、TRKC)抑制活性，因此本发明化合物及其各种晶型，药学上可接受的无机或有机盐，水合物或溶剂合物，以及含有本发明化合物为主要活性成分的药物组合物可用于预防和/或治疗与TRK激酶活性或表达量相关的疾病(例如，癌症)。
在本申请中，术语“药物组合物”是指本发明化合物与本领域通常接受的用于将生物活性化合物输送至哺乳动物(例如人)的介质的制剂。该介质包括药学上可接受的载体。药物组合物的目的是促进生物体的给药，利于活性成分的吸收进而发挥生物活性。
在本申请中，术语“药学上可接受的”是指不影响本发明化合物的生物活性或性质的物质(如载体或稀释剂)，并且相对无毒，即该物质可施用于个体而不造成不良的生物反应或以不良方式与组合物中包含的任意组分相互作用。
在本申请中，术语“药学上可接受的赋形剂”包括但不限于任何被相关的政府管理部门许可为可接受供人类或家畜使用的佐剂、载体、赋形剂、助流剂、增甜剂、稀释剂、防腐剂、染料/着色剂、矫味剂、表面活性剂、润湿剂、分散剂、助悬剂、稳定剂、等渗剂、溶剂或乳化剂。
在本申请中，术语“肿瘤”包括但不限于神经胶质瘤、肉瘤、黑色素瘤、关节软骨瘤、胆管瘤、白血病、胃肠间质瘤、组织细胞性淋巴瘤、非小细胞肺癌、小细胞肺癌、胰腺癌、肺鳞癌、肺腺癌、乳腺癌、前列腺癌、肝癌、皮肤癌、上皮细胞癌、宫颈癌、卵巢癌、肠癌、鼻咽癌、脑癌、骨癌、食道癌、黑色素瘤、肾癌、口腔癌等疾病。
在本申请中，术语“预防的”、“预防”和“防止”包括使病患减少疾病或病症的发生或恶化的可能性。
在本申请中，术语“治疗”和其它类似的同义词包括以下含义：
(i)预防疾病或病症在哺乳动物中出现，特别是当这类哺乳动物易患有该疾病或病症，但尚未被诊断为已患有该疾病或病症时；
(ii)抑制疾病或病症，即遏制其发展；
(iii)缓解疾病或病症，即，使该疾病或病症的状态消退；或者
(iv)减轻该疾病或病症所造成的症状。
在本申请中，术语“有效量”、“治疗有效量”或“药学有效量”是指服用后足以在某种程度上缓解所治疗的疾病或病症的一个或多个症状的至少一种药剂或化合物的量。其结果可以为迹象、症状或病因的消减和/或缓解，或生物系统的任何其它所需变化。例如，用于治疗的“有效量”是在临床上提供显著的病症缓解效果所需的包含本文公开化合物的组合物的量。可使用诸如剂量递增试验的技术测定适合于任意个体病例中的有效量。
在本申请中，术语“服用”、“施用”、“给药”等是指能够将化合物或组合物递送到进行生物作用的所需位点的方法。这些方法包括但不限于口服途径、经十二指肠途径、胃肠外注射(包括静脉内、皮下、腹膜内、肌内、动脉内注射或输注)、局部给药和经直肠给药。本领域技术人员熟知可用于本文所述化合物和方法的施用技术，例如在Goodman and Gilman,The Pharmacological Basis of Therapeutics,current ed.；Pergamon；and Remington’s,Pharmaceutical Sciences(current edition),Mack Publishing Co.,Easton,Pa中讨论的那些。在优选的实施方案中，本文讨论的化合物和组合物通过口服施用。
在本申请中，术语“药物组合”、“药物联用”、“联合用药”、“施用其它治疗”、“施用其它治疗剂”等是指通过混合或组合不止一种活性成分而获得的药物治疗，其包括活性成分的固定和不固定组合。术语“固定组合”是指以单个实体或单个剂型的形式向患者同时施用至少一种本文所述的化合物和至少一种协同药剂。术语“不固定组合”是指以单独实体的形式向患者同时施用、合用或以可变的间隔时间顺次施用至少一种本文所述的化合物和至少一种协同制剂。这些也应用到鸡尾酒疗法中，例如施用三种或更多种活性成分。
与现有技术相比，本发明的主要优点在于：
1.本发明化合物具有优异的药代动力学性质。
2.本发明化合物能够在荷瘤小鼠中有效抑制肿瘤生长。
3.本发明化合物能够有效的抑制KM12-LUC细胞的增殖。
4.本发明化合物能够在细胞学水平有效抑制TRKA、TRKB和TRKC的磷酸化水平。
下面结合具体实施例，进一步阐述本发明。应理解，这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法，通常按照常规条件，或按照制造厂商所建议的条件。除非另外说明，否则百分比和份数按重量计算。
本领域技术人员还应当理解，在下文所述的方法中，中间体化合物官能团可能需要由适当的保护基保护。这样的官能团包括羟基、氨基、巯基及羧酸。合适的羟基保护基包括三烷基甲硅烷基或二芳基烷基甲硅烷基(例如叔丁基二甲基甲硅烷基、叔丁基二苯基甲硅烷基或三甲基甲硅烷基)、四氢吡喃基、苄基等。合适的氨基、脒基及胍基的保护基包括叔丁氧羰基、苄氧羰基等。合适的巯基保护基包括-C(O)-R”(其中R”为烷基、芳基或芳烷基)、对甲氧基苄基、三苯甲基等。合适的羧基保护基包括烷基、芳基或芳烷基酯类。
保护基可根据本领域技术人员已知的和如本文所述的标准技术来引入和除去。保护基的使用详述于Greene,T.W.与P.G.M.Wuts,Protective Groups in Organi Synthesis,(1999),4th Ed.,Wiley中。保护基还可为聚合物树脂。
实施例
中间体A的合成
Figure PCTCN2020129913-appb-000020
(R,E)-N-(2,5-二氟苯亚甲基)-2-甲基丙烷-2-亚磺酰胺
Figure PCTCN2020129913-appb-000021
将2,5-二氟苯甲醛(5g,35.2mmol)与(R)-2-甲基丙烷-2-亚磺酰胺(4.47g,36.9mmol)溶于二氯甲烷(50mL)中，室温下加入碳酸铯(8.0g,24.6mmol),然后升温至50℃反应3小时，TLC显示反应完毕，过滤，滤饼用二氯甲烷洗涤，滤液用盐水洗涤，无水硫酸钠干燥，旋干得黄色油状液体(9g)。
(R)-N-((R)-1-(2,5-二氟苯基)-3-(1,3-二噁烷-2-基)丙基)-2-甲基丙烷-2-亚磺酰胺
Figure PCTCN2020129913-appb-000022
将镁屑(2g,83.3mmol)溶于四氢呋喃(72mL)中，氮气保护，于40℃下将二异丁基氢化铝的四氢呋喃溶液(0.1mL,1.5M,0.15mmol)滴加入体系，40℃反应0.5h,然后将2-(2-溴乙基)-1,3-二噁烷(14.3g,73.47mmol)的四氢呋喃(40mL)溶液缓慢滴加 入体系并控制温度在40-50℃，滴完后保持40℃搅拌1h。撤掉加热，将反应体系冷却至-30℃，然后将(R,E)-N-(2,5-二氟苯亚甲基)-2-甲基丙烷-2-亚磺酰胺(9g,36.73mmol)的四氢呋喃(40mL)溶液滴加入体系，控制其温度在-30℃-20℃，滴完后，于-30℃搅拌2h,TLC显示反应完毕,用10％的柠檬酸水溶液淬灭并控制温度在10℃，用二氯甲烷萃取，有机相用饱盐水洗涤，无水硫酸钠干燥，旋干得无色油状液体(15.8g)。
(R)-2-(2,5-二氟苯基)吡咯烷
Figure PCTCN2020129913-appb-000023
室温下将(R)-N-((R)-1-(2,5-二氟苯基)-3-(1,3-二噁烷-2-基)丙基)-2-甲基丙烷-2-亚磺酰胺(15.8g,43.76mmol)加入到三氟乙酸(32mL)与水(8mL)的混合溶液中，室温搅拌1h,然后将三氟乙酸(60mL)加入到体系，三乙基硅烷(15.2g,131.1mmol)滴加入体系，反应室温过夜，LCMS监测反应完毕，旋掉大部分三氟乙酸,剩余溶于盐酸(1N,100mL)并搅拌0.5h,用甲基叔丁基醚萃取，有机相用盐酸(1N,50mL)洗涤，合并水相，水相用40％氢氧化钠水溶液调节pH＝11,然后用二氯甲烷萃取，合并有机相，饱盐水洗涤，无水硫酸钠干燥，旋干得油状液体(6.7g)。
中间体B的合成
Figure PCTCN2020129913-appb-000024
(S)-N-((S)-1-(2,5-二氟苯基)丁-3-烯-1-基)-2-甲基丙烷-2-亚磺酰胺
Figure PCTCN2020129913-appb-000025
将(R)-N-(2,5-二氟苯亚甲基)-2-甲基丙烷-2-亚磺酰胺(30g,122.45mmol)于室温下加入到饱和溴化钠(480mL)的水溶液中,加入In(42g,367.35mmol),然后加入烯丙基溴化镁(42mL,489.8mmol),室温反应6小时,TLC监测反应完毕，用饱和碳酸氢钠溶液淬灭，过滤，滤液用乙酸乙酯萃取，饱盐水洗涤，无水硫酸钠干燥，旋干得(S)-N-((S)-1-(2,5-二氟苯基)丁-3-烯-1-基)-2-甲基丙烷-2-亚磺酰胺,黄色固体(35g).
(S)-N-((1S)-1-(2,5-二氟苯基)-2-(环氧乙烷-2-基)乙基)-2-甲基丙烷-2-亚磺酰胺
Figure PCTCN2020129913-appb-000026
将(S)-N-((S)-1-(2,5-二氟苯基)丁-3-烯-1-基)-2-甲基丙烷-2-亚磺酰胺(35g,121.95mmol)溶于二氯甲烷(800mL)中,于室温下分批加入间氯过氧苯甲酸(80g,365.85mmol),室温搅拌过夜，TLC监测反应完毕，反应液用饱和碳酸氢钠与饱和硫代硫酸钠溶液洗涤，饱盐水洗涤，无水硫酸钠干燥，旋干得(S)-N-((S)-1-(2,5-二氟苯基)丁-3-烯-1-基)-2-甲基丙烷-2-亚磺酰胺，黄色固体(31g,收率79％).
(3R，5R)-1-(叔丁基磺酰基)-5-(2,5-二氟苯基)吡咯烷-3-醇
Figure PCTCN2020129913-appb-000027
将(S)-N-((S)-1-(2,5-二氟苯基)丁-3-烯-1-基)-2-甲基丙烷-2-亚磺酰胺(31g,97.18mmol)溶于N,N-二甲基甲酰胺(300mL)中，室温下加入碳酸钾(40g,291.53mmol),碘化钾(16g,97.18mmol),加热至100℃反应1小时，TLC监测反应完毕，待反应液冷却至室温，过滤，滤液打入水中，用乙酸乙酯萃取，合并有机相，饱盐水洗涤，无水硫酸钠干燥，旋干过柱纯化(石油醚/乙酸乙酯＝10/1—5/1)得到化合物(3R，5R)-1-(叔丁基磺酰基)-5-(2,5-二氟苯基)吡咯烷-3-醇(7.5g)。
(2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷
Figure PCTCN2020129913-appb-000028
将(3R，5R)-1-(叔丁基磺酰基)-5-(2,5-二氟苯基)吡咯烷-3-醇(2.0g,6.27mmol)溶于二氯甲烷(50ml)中，冷却至零下60℃，将DAST(2ml)滴加入体系，然后自然升至室温并搅拌过夜，LCMS监测反应完毕，反应液加入二氯甲烷稀释，将其缓慢倒入冰水中，分液，有机相用饱盐水洗涤，无水硫酸钠干燥，旋干过柱纯化(石油醚/乙酸乙酯＝10/1)得到(2R，4S)-1-(叔丁基磺酰基)-2-(2,5-二氟苯基)-4-氟，黄色固体(1.2g,收率60％)。
(2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷
Figure PCTCN2020129913-appb-000029
向(2R，4S)-1-(叔丁基磺酰基)-2-(2,5-二氟苯基)-4-氟(500mg，1.55mmol)的二氯甲烷溶液(20mL)中加入三氟甲磺酸(0.7mL)，反应2小时，溶剂旋干，用2M的氢氧化钠溶液洗涤，加入乙酸乙酯萃取，分液，有机相用饱盐水洗涤，无水硫酸钠干燥，旋干过柱纯化(石油醚/乙酸乙酯＝4/1)得到(2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷，黄色固体(305mg,收率99％)。
中间体C的合成
Figure PCTCN2020129913-appb-000030
6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)-3-硝基咪唑并[1,2-b]哒嗪
Figure PCTCN2020129913-appb-000031
向(2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷(150mg,0.75mmol),6-氯-3-硝基咪唑并[1,2-b]哒嗪(222mg,1.12mmol)的二甲基亚砜(2mL)溶液中加入三乙胺(151mg,1.5mmol).反应液100℃搅拌16小时。LCMS显示大部分原料消失。反应液通过制备型高效液相色谱纯化获得黄色固体(150mg,收率55％)。
MS(ESI):m/z＝364[M+H] +.
6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-胺
Figure PCTCN2020129913-appb-000032
向6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)-3-硝基咪唑并[1,2-b]哒嗪(60mg,0.16mmol)的甲醇(20mL)溶液中加入钯碳(15mg).反应液通过水泵用氢气球置换三次后室温搅拌8小时。LCMS显示大部分原料消失。反应液通过硅藻土过滤，并用二氯甲烷(20mL)冲洗。滤液浓缩后通过制备型高效液相色谱纯化获得黄色固体(30mg，收 率57％)。
MS(ESI):m/z＝334[M+H] +.
中间体D的合成：
6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-甲醛
Figure PCTCN2020129913-appb-000033
乙基6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-羧酸酯
Figure PCTCN2020129913-appb-000034
向一封管中依次加入乙基6-氯咪唑并[1,2-b]哒嗪-3-羧酸酯(400mg,1.78mmol),(2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷(393mg,1.95mmol)，氟化钾(206mg,3.56mmol)和二甲亚砜(4mL)，加热到120℃反应16个小时，冷却到室温，倒入水中，加入乙酸乙酯，有机相分离，干燥，旋干过柱纯化(石油醚/乙酸乙酯＝1/1)得到白色固体(475mg,收率68％)。
MS(ESI):m/z＝391[M+H] +.
(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)甲醇
Figure PCTCN2020129913-appb-000035
将乙基6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-羧酸酯(476mg,1.22mmol)加入到四氢呋喃(8mL)中，冷却到0℃。滴加四氢铝锂四氢呋喃溶液(1.8mL，1M)。反应3个小时，依次加入水，15％氢氧化钠溶液，水淬灭反应，产生固体过滤，滤液旋干过柱纯化(乙酸乙酯/甲醇＝30/1)得到白色固体(380mg,收率90％)。
MS(ESI):m/z＝349[M+H] +.
6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-甲醛
Figure PCTCN2020129913-appb-000036
将(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)甲醇(120mg,0.34mmol),二氧化锰(1.5g,17.20mmol)和四氢呋喃(10mL)混合，加热到45℃反应16个小时，冷却到室温，把固体过滤掉，滤饼用乙酸乙酯洗涤，有机相旋干，得到粗产品(200mg)。
MS(ESI):m/z＝347[M+H] +.
实施例1：
(S)-1-(6-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)吡啶-3-基)吡咯烷-3-醇
Figure PCTCN2020129913-appb-000037
((5-溴吡啶-2-基)甲基)三苯基磷氯化物
Figure PCTCN2020129913-appb-000038
将5-溴-2-(氯甲基)吡啶(2.3g,8.68mmol)，三苯基膦(2.5g,9.55mmol)和乙腈(16mL)混合，加热到50℃反应16个小时，反应完毕后，将溶剂旋干，得到固体用石油醚/乙酸乙酯＝10:1打浆，得到粉红色固体(3.5g,收率98％)。
MS(ESI):m/z＝432[M+H] +.
3-((E)-2-(5-溴吡啶-2-基)乙烯基)-6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪
Figure PCTCN2020129913-appb-000039
将((5-溴吡啶-2-基)甲基)三苯基磷氯化物(168mg,0.39mmol)和四氢呋喃(5mL)混合，冷却到0℃，加入氢化钠(15mg,0.39mmol)，在此温度下反应半个小时，将6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-甲醛(90mg,0.26mmol)溶解在四氢呋喃(5mL)中，滴加到上述溶液中，室温下反应16个小时，加入水淬灭反应，反应液用乙酸乙酯萃取，有机相分离，干燥，旋干过柱纯化(石油醚/乙酸乙酯＝1/2)得到黄色固体(108mg,收率83％)。
MS(ESI):m/z＝349[M+H] +.
(S)-1-(6-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)吡啶-3-基)吡咯烷-3-醇
Figure PCTCN2020129913-appb-000040
将3-((E)-2-(5-溴吡啶-2-基)乙烯基)-6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪(108mg,0.22mmol),(S)-吡咯烷-3-醇(92mg,1.08mmol),三(二亚苄基丙酮)二钯(39mg,0.04mmol)，2-二环己基磷-2',4',6'-三异丙基联苯(41mg,0.08mmol)，碳酸铯(176mg,0.54mmol)和甲苯(10mL)混合，加热到110℃反应16个小时，反应完毕后，加入水和二氯甲烷萃取，有机相分离，干燥，旋干过柱纯化(乙酸乙酯/甲醇＝5/1)得到黄色固体(45mg,收率41％)。
MS(ESI):m/z＝507[M+H] +.
1H NMR(400MHz,DMSO-d 6)δ7.94(d,J＝2.8Hz,1H),7.82(d,J＝10.0Hz,1H),7.73(s,1H),7.36–7.20(m,5H),7.08–7.03(m,,1H),6.90(dd,J＝2.8,8.8Hz,1H),6.78(d,J＝10.0Hz,1H),5.52(d,J＝53.2Hz,1H),5.40(t,J＝8.4Hz,1H),4.98(d,J＝4.0Hz,1H),4.41(s,1H),4.23–4.02(m,2H),3.48-3.42(m,3H),3.16-3.13(m,1H),2.87–2.77(m,1H),2.29-2.15(m,1H),2.15–1.99(m,1H),1.92–1.87(m,1H).
实施例2
4-(6-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)吡啶-3-基)吗啉
Figure PCTCN2020129913-appb-000041
采用类似于实施例1的条件，替换相应的起始原料,得4-(6-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)吡啶-3-基)吗啉(35mg,收率65％)，为黄色固体。
MS(ESI):m/z＝507[M+H] +.
1H NMR(400MHz,DMSO-d 6)δ8.31(d,J＝2.8Hz,1H),7.85(d,J＝10.0Hz,1H),7.77(s,1H),7.46–7.20(m,6H),7.08–7.03(m,,1H),6.80(d,J＝10.0Hz,1H),5.66(d,J＝52.8Hz,1H),5.40(t,J＝8.8Hz,1H),4.23–4.02(m,2H),3.75-3.73(m,4H),3.21-3.18(m,4H),2.87–2.77(m,1H),2.29-2.15(m,1H).
实施例3
(S)-1-(2-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)嘧啶-5-基)吡咯烷-3-醇
Figure PCTCN2020129913-appb-000042
采用类似于实施例1的条件，替换相应的起始原料,得(S)-1-(2-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)嘧啶-5-基)吡咯烷-3-醇(19mg,收率15％)，为黄色固体。
MS(ESI):m/z＝508[M+H] +.
1H NMR(400MHz,DMSO-d 6)δ8.16(s,2H),7.89(s,1H),7.86(d,J＝9.6Hz,1H),7.68(d,J＝16.0Hz,1H),7.40(d,J＝16.0Hz,1H),7.31–7.26(m,2H),7.11–7.07(m,,1H),6.76(d,J＝10.0Hz,1H),5.58(d,J＝52.4Hz,1H),5.40(t,J＝8.0Hz,1H),5.05(d,J＝3.6Hz,1H),4.46(s,1H),4.26–4.10(m,2H),3.53-3.36(m,3H),3.26-3.22(m,1H),2.92–2.81(m,1H),2.07-2.04(m,1H),1.97–1.94(m,1H).
实施例4
(S)-1-(6-(((6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)氨基)甲基)吡啶-3-基)吡咯烷-3-醇
Figure PCTCN2020129913-appb-000043
(S)-5-(3-羟基吡咯烷-1-基)甲基吡啶醛
Figure PCTCN2020129913-appb-000044
向5-氟吡啶-2-醛(200mg,1.60mmol)和(S)-3-吡咯烷醇(139mg,1.6mmol)的乙腈(10mL)溶液中加入碳酸钾(442mg,3.2mmol)。反应液加热到80℃，并搅拌24小时。加入水(50mL),用乙酸乙酯(50mL*2)萃取.有机相,干燥,过滤，浓缩，柱层析(乙酸乙酯)得到黄色固体(217mg,收率70.6％)。
MS(ESI):m/z＝193[M+H] +.
(S)-1-(6-(((6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)氨基)甲基)吡啶-3-基)吡咯烷-3-醇
Figure PCTCN2020129913-appb-000045
向6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-胺(60mg,0.18mmol)和(S)-5-(3-羟基吡咯烷-1-基)甲基吡啶醛(104mg,0.54mmol)的甲醇(5mL)溶液中加入醋酸(0.05mL)。反应液加热到40℃，搅拌过夜。把反应液降到室温，加入氰基硼氢化钠(34mg,0.54mmol)后，室温搅拌1小时。加入水(50mL),用二氯甲烷/甲醇＝10/1(50mL*2)萃取.有机相,干燥,浓缩，制备得到标题黄色固体(16.4mg,收率17.9％)。
MS(ESI):m/z＝510[M+H] +.
1H NMR(400MHz,DMSO-d 6)δ7.82(d,J＝2.7Hz,1H),7.55(d,J＝9.7Hz,1H),7.29–7.15(m,2H),7.19-7.09(m,2H),6.81(dd,J＝8.5,2.9Hz,1H),6.68(s,1H),6.39(d,J＝9.7Hz,1H),5.55(s,1H),5.42(s,1H),5.33–5.26(m,1H),5.26-5.20(m,1H),4.94(d,J ＝3.8Hz,1H),4.40-4.32(m,1H),4.22(d,J＝6.3Hz,2H),4.05(d,J＝30.9Hz,2H),3.37(dd,J＝10.1,4.9Hz,1H),3.27-3.22(m,1H),3.05(d,J＝8.7Hz,1H),2.81–2.68(m,1H),2.31–2.10(m,2H),2.03-1.93(m,1H),1.90-1.80(m,1H).
实施例5
(3S)-1-(6-(1-((6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)氨基)-2,2,2-三氟乙基)吡啶-3-基)吡咯烷-3-醇
Figure PCTCN2020129913-appb-000046
2,2,2-三氟-1-(5-氟吡啶-2-基)乙烷-1-醇
Figure PCTCN2020129913-appb-000047
将5-氟吡啶-2-醛(1.0g,8.0mmol)溶解在四氢呋喃(15mL)里面，冷却到0℃，氮气保护下缓慢加入三氟甲基三甲基硅烷(1.7g,12.0mmol)。反应液在0℃搅拌15分钟，滴加四丁基氟化胺四氢呋喃溶液(20mL，1.0M)，反应升到室温，搅拌16小时。反应完毕后加入水和乙酸乙酯，分离有机相，干燥，浓缩，柱层析(石油醚/乙酸乙酯＝4/1)得到棕色油状物(1.16g,收率74％)。
2,2,2-三氟-1-(5-氟吡啶-2-基)乙烷-1-酮
Figure PCTCN2020129913-appb-000048
将2,2,2-三氟-1-(5-氟吡啶-2-基)乙烷-1-醇(1.16g,5.9mmol),戴斯-马丁氧化剂(3.0g,7.1mmol)和二氯甲烷(25mL)混合，室温搅拌16个小时，过滤掉固体，滤液依次用饱和碳酸钠，饱和硫代硫酸钠洗涤，干燥，浓缩，柱层析(石油醚/乙酸乙酯＝4/1)得到棕色油状物(350mg,收率46％)。
MS(ESI):m/z＝196[M+H] +.
(S)-2,2,2-三氟-1-(5-(3-羟基吡咯烷-1-基)吡啶-2-基)乙烷-1-酮
Figure PCTCN2020129913-appb-000049
将2,2,2-三氟-1-(5-氟吡啶-2-基)乙烷-1-酮(200mg,1.0mmol)，(S)-3-吡咯烷醇(170mg,2.0mmol)，N,N'-二异丙基乙胺(250mg,2.0mmol)和N-甲基吡咯烷酮(4mL)混合，加热到60℃搅拌2个小时，反应完毕后，冷却到室温，反应液用反向制备纯化，得到棕色固体(252mg,收率97％)。
MS(ESI):m/z＝194[M+H] +.
(3S)-1-(6-(1-((6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)氨基)-2,2,2-三氟乙基)吡啶-3-基)吡咯烷-3-醇
Figure PCTCN2020129913-appb-000050
将6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-胺(104mg,0.4mmol)，(S)-2,2,2-三氟-1-(5-(3-羟基吡咯烷-1-基)吡啶-2-基)乙烷-1-酮(132mg,0.4mmol)和二氯甲烷混合，向此混合物中加入三甲基铝的甲苯溶液(0.6mL,1M)，此反应液在30℃下搅拌3天。再加入硼烷二甲硫醚的四氢呋喃溶液(1.0mL,2M)，在30℃下搅拌2天。加入20％氢氧化钠溶液淬灭反应，用二氯甲烷萃取，有机相分离，干燥，浓缩，反向制备得到白色固体(8.0mg,收率3.5％)。
MS(ESI):m/z＝578[M+H] +.
1H NMR(400MHz,DMSO-d 6)δ7.85(dd,J＝2.7,52.1Hz,1H),7.64–7.58(m,1H),7.30–7.03(m,4H),6.97–6.81(m,2H),6.58–6.49(m,1H),5.78–5.40(m,2H),5.40–5.18(m,2H),4.99–4.93(m,1H),4.37(s,1H),4.20–3.90(m,2H),3.43–3.34(m,1H),3.13–3.03(m,1H),2.84–2.70(m,1H),2.03–1.82(m,2H).
实施例6
(S)-1-(6-((6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)氨基)吡啶-3-基)吡咯烷-3-醇
Figure PCTCN2020129913-appb-000051
(S)-1-(6-氯吡啶-3-基)吡咯烷-3-醇
Figure PCTCN2020129913-appb-000052
向2-氯-5-氟吡啶(200mg,1.52mmol)和(S)-吡咯烷-3-醇(132mg,1.52mmol)的N-甲基吡咯烷酮(4mL)溶液中加入N,N-二异丙基乙胺(590mg,4.56mmol)后,加热到100℃反应40小时。反应液反相制备得到白色固体(88mg,收率29.1％)，为白色固体。
MS(ESI):m/z＝199[M+H] +.
(S)-1-(6-((6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)氨基)吡啶-3-基)吡咯烷-3-醇
Figure PCTCN2020129913-appb-000053
向6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-胺(100mg,0.30mmol)，(S)-1-(6-氯吡啶-3-基)吡咯烷-3-醇(72mg,0.36mmol)和碳酸铯(196mg,0.60mmol)的甲苯(10mL)溶液中加入三(二亚苄基丙酮)二钯(55mg,0.06mmol)和4,5-双二苯基膦-9,9-二甲基氧杂蒽(70mg,0.12mmol)。反应液升温至120℃，搅拌过夜。加入水(50mL),用二氯甲烷/甲醇＝10/1(50mL*2)萃取.合并有机相,干燥,过滤，浓缩，制备得到黄色固体(20mg,收率13.5％)。
MS(ESI):m/z＝496[M+H] +.
1H NMR(400MHz,CD 3OD)δ8.30(s,1H),7.65(d,J＝9.8Hz,1H),7.53(s,1H),7.38(d,J＝2.7Hz,1H),7.09–6.95(m,3H),6.93-6.85(m,1H),6.74(d,J＝10.0Hz,1H),6.70(d,J＝9.2Hz,1H),5.49-5.32(m,2H),4.57–4.48(m,1H),4.11(s,1H),4.09–3.97(m,1H),3.50–3.36(m,2H),3.32-3.28(m,1H),3.16(d,J＝9.6Hz,1H),2.87–2.74(m,1H),2.28–2.09(m,2H),2.06-1.97(m,1H).
实施例7
1-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)-3-(5-((S)-3-羟基吡咯烷-1-基)吡啶-2-基)脲
Figure PCTCN2020129913-appb-000054
(S)-1-(6-硝基吡啶-3-基)吡咯烷-3-醇
Figure PCTCN2020129913-appb-000055
向5-氟-2-硝基吡啶(200mg,1.41mmol)和(S)-3-吡咯烷醇(184mg,2.11mmol)的N-甲基吡咯烷酮(4mL)溶液中加入N,N-二异丙基乙胺(547mg,4.23mmol)。反应液加热到100℃，并搅拌过夜。反应液浓缩，反相制备得到黄色固体(230mg,收率78.0％)。
MS(ESI):m/z＝209[M+H] +.
(S)-1-(6-氨基吡啶-3-基)吡咯烷-3-醇
Figure PCTCN2020129913-appb-000056
向(S)-1-(6-硝基吡啶-3-基)吡咯烷-3-醇(230mg,1.1mmol)的甲醇(8mL)溶液中加入10％钯炭(100mg)。反应液氢气置换三次，在氢气球下室温搅拌2小时。反应液过滤，浓缩，得到粉色固体(190mg,收率96.4％)。
MS(ESI):m/z＝180[M+H] +.
1-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)-3-(5-((S)-3-羟基吡咯烷-1-基)吡啶-2-基)脲
Figure PCTCN2020129913-appb-000057
在0℃时向三光气(18mg,0.06mmol)的二氯甲烷(3mL)溶液中滴加6-((2R,4S)-2- (2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-胺(40mg,0.12mmol)的二氯甲烷(1mL)溶液，以及三乙胺(24mg,0.24mmol)。混合物在0℃下半个小时，滴加(S)-1-(6-氨基吡啶-3-基)吡咯烷-3-醇(32mg,0.18mmol)的二氯甲烷(2mL)和N,N-二甲基甲酰胺(1mL)混合溶液，室温搅拌1个小时。加入甲醇(2mL)，浓缩，反向制备得到黄色固体(15mg,收率23％)。
MS(ESI):m/z＝539[M+H] +.
1H NMR(400MHz,CD 3OD)δ7.68(d,J＝2.5Hz,1H),7.60–7.55(m,2H),7.12-7.07(m,1H),7.06–6.90(m,4H),6.56(d,J＝9.8Hz,1H),5.57-5.40(m,2H),4.62-4.54(m,1H),4.59-4.30(m,1H),4.23–4.09(m,1H),3.54–3.42(m,2H),3.40-3.32(m,1H),3.22(d,J＝10.0Hz,1H),2.97-2.86(m,1H),2.37–2.22(m,1H),2.22–2.13(m,1H),2.08-1.99(m,1H).
实施例8
4-(2-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基) 乙烯基)嘧啶-5-基)吗啉
Figure PCTCN2020129913-appb-000058
采用类似于实施例1的条件，替换相应的起始原料,得 4-(2-((E)-2-(6-((2R,4S)-2- (2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)嘧啶-5-基)吗啉(48mg,收率67％)，为黄色固体。
MS(ESI):m/z＝508[M+H] +.
1H NMR(400MHz,DMSO-d 6)δ8.50(s,2H),7.88(s,1H),7.85(d,J＝10.0Hz,1H),7.73(d,J＝16.0Hz,1H),7.37(d,J＝16.0Hz,1H),7.28–7.21(m,2H),7.08–7.03(m,1H),6.77(d,J＝9.6Hz,1H),5.53(d,J＝53.2Hz,1H),5.35(t,J＝8.8Hz,1H),4.21–4.05(m,2H),3.76–3.74(m,4H),3.26–3.24(m,4H),2.87–2.77(m,1H),2.29–2.13(m,1H).
实施例9
4-(6-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基) 乙烯基)吡啶-3-基)哌嗪-2-酮
Figure PCTCN2020129913-appb-000059
叔-丁基4-(6-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)吡啶-3-基)-2-羰基哌嗪-1-羧酸酯
Figure PCTCN2020129913-appb-000060
采用类似于实施例1的条件，替换相应的起始原料,得叔-丁基4-(6-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)吡啶-3-基)-2-羰基哌嗪-1-羧酸酯(60mg,收率54％)，为黄色固体。
MS(ESI):m/z＝620[M+H] +.
4-(6-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基) 乙烯基)吡啶-3-基)哌嗪-2-酮
Figure PCTCN2020129913-appb-000061
将叔-丁基4-(6-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)吡啶-3-基)-2-羰基哌嗪-1-羧酸酯(60mg,0.096mmol)与盐酸乙酸乙酯溶液(2mL，4M)混合，搅拌2小时，浓缩，反向制备得到 4-(6-((E)-2-(6-((2R,4S)-2- (2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)吡啶-3-基)哌嗪-2-酮为黄色固体(7mg,收率14％)。
MS(ESI):m/z＝520[M+H] +.
1H NMR(400MHz,DMSO-d 6)δ8.29(s,1H),8.10(s,1H),7.84(d,J＝10.0Hz,1H),7.76(s,1H),7.44–7.21(m,6H),7.08–7.03(m,1H),6.81(d,J＝9.6Hz,1H),5.52(d,J＝53.2Hz,1H),5.40(t,J＝8.8Hz,1H),4.23–4.01(m,2H),3.81(s,2H),3.50–3.47(m,2H),2.87–2.77(m,1H),2.29–2.12(m,1H),1.99–1.92(m,1H).
实施例10
(S)-1-(5-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)吡嗪-2-基)吡咯烷-3-醇
Figure PCTCN2020129913-appb-000062
采用类似于实施例1的条件，替换相应的起始原料,得(S)-1-(5-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)吡嗪-2-基)吡咯烷-3-醇(19mg,收率9％)，为黄色固体。
MS(ESI):m/z＝508[M+H] +.
1H NMR(400MHz,DMSO-d 6)δ8.05(s,1H),8.00(s,1H),7.83(d,J＝9.6Hz,1H),7.73(s,1H),7.40–7.29(m,2H),7.24–7.18(m,2H),7.08–7.03(m,1H),6.79(d,J＝8.8Hz,1H),5.51(d,J＝53.2Hz,1H),5.40(t,J＝8.8Hz,1H),5.01(d,J＝3.6Hz,1H),4.40(s,1H),4.22–4.02(m,3H),3.63–3.48(m,3H),3.04–2.75(m,2H),2.17–1.83(m,2H).
实施例11
4-(5-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)吡嗪-2-基)哌嗪-2-酮
Figure PCTCN2020129913-appb-000063
3-溴-6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪
Figure PCTCN2020129913-appb-000064
向一封管中依次加入3-溴-6-氯咪唑并[1,2-b]哒嗪(500mg,2.17mmol),(2R,4S)-2- (2,5-二氟苯基)-4-氟吡咯烷(459mg,2.28mmol)，氟化钾(377mg,6.51mmol)和二甲亚砜(4mL)，加热到120℃反应16个小时，冷却到室温，倒入水中，加入乙酸乙酯，有机相分离，干燥，旋干过柱纯化(石油醚/乙酸乙酯＝1/1)得到棕色固体(500mg,收率58％)。
MS(ESI):m/z＝397[M+H] +.
4-(5-氯吡嗪-2-基)哌嗪-2-酮
Figure PCTCN2020129913-appb-000065
向2,5-二氯吡嗪(400mg,2.70mmol)和哌嗪-2-酮(405mg,4.05mmol)的乙腈(6mL)混合物中加入N,N-二异丙基乙胺(1.04g,8.1mmol)。反应液加热到70℃，并搅拌24小时。加入水(50mL),用乙酸乙酯(50mL*2)萃取.有机相,干燥,过滤，浓缩，柱层析(二氯甲烷/甲醇＝20/1)得到白色固体(200mg,收率35％)。
MS(ESI):m/z＝213[M+H] +.
4-(5-乙烯基吡嗪-2-基)哌嗪-2-酮
Figure PCTCN2020129913-appb-000066
向4-(5-氯吡嗪-2-基)哌嗪-2-酮(200mg,0.94mmol)，4,4,5,5-四甲基-2-乙烯基-1,3,2-二噁硼戊环(433mg,2.81mmol)和碳酸钾(324mg,2.35mmol)的二氧六环(4mL)和水(1mL)混合物中加入[1,1'-双(二苯基膦基)二茂铁]二氯化钯(77mg,0.094mmol)。反应液升温至110℃，搅拌过夜。加入水(50mL),用二氯甲烷/甲醇＝10/1(50mL*2)萃取.合并有机相,干燥,过滤，浓缩，柱层析(二氯甲烷/甲醇＝20/1)得到白色固体(150mg,收率77％)。
MS(ESI):m/z＝205[M+H] +.
4-(5-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)吡嗪-2-基)哌嗪-2-酮
Figure PCTCN2020129913-appb-000067
向4-(5-乙烯基吡嗪-2-基)哌嗪-2-酮(124mg,0.607mmol)，3-溴-6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪(80mg,0.202mmol)和三乙胺(102mg,1.01mmol)的N,N-二甲基甲酰胺(2mL)混合物中加入醋酸钯(9mg,0.04mmol)和2-二环己基磷-2',4',6'-三异丙基联苯(38mg,0.08mmol)，。反应液升温至120℃，微波条件下反应1小时。反向制备得到4-(5-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)吡嗪-2-基)哌嗪-2-酮为黄色固体(17mg,收率16％)。
MS(ESI):m/z＝521[M+H] +.
1H NMR(400MHz,DMSO-d 6)δ8.34(s,1H),8.15(s,1H),8.12(s,1H),7.85(d,J＝10.0Hz,1H),7.76(s,1H),7.46–7.32(m,1H),7.26–7.18(m,2H),7.07–7.02(m,1H),6.81(d,J＝9.6Hz,1H),5.51(d,J＝53.2Hz,1H),5.40(t,J＝8.8Hz,1H),4.23–4.02(m,4H),3.81–3.79(m,2H),3.29–3.26(m,2H),2.83–2.80(m,2H),2.29–2.25(m,1H).
实施例12
(R)-1-(5-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)吡嗪-2-基)吡咯烷-3-醇
Figure PCTCN2020129913-appb-000068
采用类似于实施例11的条件，替换相应的起始原料,得(R)-1-(5-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)吡嗪-2-基)吡咯烷-3-醇(15mg,收率12％)，为黄色固体。
MS(ESI):m/z＝508[M+H] +.
1H NMR(400MHz,DMSO-d 6)δ8.09(s,1H),8.04(s,1H),7.87(d,J＝10.0Hz,1H),7.77(s,1H),7.44–7.33(m,2H),7.28–7.22(m,2H),7.11–7.06(m,1H),6.83(d,J＝10.0Hz,1H),5.55(d,J＝53.2Hz,1H),5.44(t,J＝8.8Hz,1H),5.04(d,J＝3.6Hz,1H),4.44(s,1H),4.23–4.08(m,2H),3.60–3.42(m,2H),2.87–2.84(m,2H),2.32–1.92(m,4H).
实施例13
(S)-1-(6-((E)-2-(5-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)吡唑并[1,5-a]嘧啶-3- 基)乙烯基)吡啶-3-基)吡咯烷-3-醇
Figure PCTCN2020129913-appb-000069
向3-((E)-2-(5-溴吡啶-2-基)乙烯基)-5-((2R，4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)吡唑并[1,5-a]嘧啶(230mg,0.43mmol),(S)-3-吡咯烷醇(187mg,2.15mmol),和碳酸铯(350mg,1.08mmol)的甲苯(7mL)溶液中加入三(二亚苄基丙酮)二钯(79mg,0.086mmol)和2-二环己基磷-2,4,6-三异丙基联苯(82mg,0.172mmol)。反应液氩气保护110℃搅拌2小时,后加水(100mL)稀释,用二氯甲烷萃取(100mL*1).有机相干燥,浓缩，残渣通残渣经Prep-HPLC分离(乙腈/水(含0.1％NH4HCO3)梯度冲洗)得到标题化合物得到标题化合物(S)-1-(6-((E)-2-(5-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)吡唑并[1,5-a]嘧啶-3-基)乙烯基)吡啶-3-基)吡咯烷-3-醇(8.6mg,收率3.9％)，为黄色固体。
MS(ESI):m/z＝507.0[M+H] +.
1H NMR(400MHz,CD 3OD)δ8.35(d,J＝6.5Hz,1H),7.96(s,1H),7.78(d,J＝2.8Hz,1H),7.40-7.30(m,1H),7.28–6.83(m,5H),6.60-6.05(m,2H),5.63-5.35(m,2H),4.60-4.55(m,1H),4.20-4.04(m,1H),3.62–3.35(m,3H),3.28–3.23(m,2H),2.97–2.83(m,1H),2.36–1.96(m,3H).
实施例14
6-(((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)-3-((E)-4-(哌嗪-1-基)苯乙烯基)咪唑[1,2-b]哒嗪
实施例15
6-(((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)-3-((Z)-4-(哌嗪-1-基)苯乙烯基)咪唑[1,2-b]哒嗪
Figure PCTCN2020129913-appb-000070
3-((E)-4-溴代苯乙烯基)-6-(((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪
Figure PCTCN2020129913-appb-000071
3-((Z)-4-溴代苯乙烯基)-6-(((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪
Figure PCTCN2020129913-appb-000072
向4-溴苄基三苯基溴化磷(236mg,0.46mmol)的四氢呋喃(5mL)溶液中0℃加入60％氢化钠(18mg,0.46mmol)。反应液0℃搅拌30分钟后缓慢滴加5-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)吡唑并[1,5-a]嘧啶-3-甲醛(80mg,0.23mmol)后缓慢升至室温并搅拌6小时。反应液用水(0.1mL)淬灭,浓缩，残渣通过正相柱层析(石油醚:乙酸乙酯＝10:1)纯化，得到标题化合物
3-((E)-4-溴代苯乙烯基)-6-(((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪(80mg,收率69.7％)，为黄色固体。
MS(ESI):m/z＝498.9[M+H] +.
3-((Z)-4-溴代苯乙烯基)-6-(((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪(30mg,收率26.1％)，为黄色固体
MS(ESI):m/z＝499.0[M+H] +.
叔丁基4-(4-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)苯基)哌嗪-1-羧酸酯
Figure PCTCN2020129913-appb-000073
向3-((E)-4-溴代苯乙烯基)-6-(((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪(80mg,0.16mmol),N-叔丁氧羰基-哌嗪(89mg,0.46mmol),和碳酸铯(104mg,0.32mmol)的二氧六环(12mL)溶液中加入三(二亚苄基丙酮)二钯(15mg,0.016mmol)和4，5-双二苯基膦-9,9-二甲基氧杂蒽(19mg,0.032mmol)。反应液氩气保护100℃搅拌3小时后加水(50mL)稀释,用二氯甲烷萃取(50mL*1)。有机相干燥,浓缩，残渣通过正相柱层析(乙酸乙酯)纯化，得到标题化合物叔丁基4-(4-((E)-2-(6- ((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)苯基)哌嗪-1-羧酸酯(50mg,收率51.7％)，为黄色油状物。
MS(ESI):m/z＝605.1[M+H] +.
6-(((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)-3-((E)-4-(哌嗪-1-基)苯乙烯基)咪唑[1,2-b]哒嗪
Figure PCTCN2020129913-appb-000074
向叔丁基4-(4-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)苯基)哌嗪-1-羧酸酯(50mg,0.083mmol)的乙酸乙酯(2mL)溶液中加入4N盐酸乙酸乙酯(10mL)。反应室温搅拌1小时后浓缩，后加二氯甲烷(50mL)和水(5mL)稀释,用饱和碳酸氢钠水溶液洗(50mL*1)，饱和氯化钠水溶液洗(50mL*1).有机相干燥,浓缩，残渣通残渣经Prep-HPLC分离(乙腈/水(含0.1％NH 4HCO 3)梯度冲洗)得到标题化合物6-(((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)-3-((E)-4-(哌嗪-1-基)苯乙烯基)咪唑[1,2-b]哒嗪(12.8mg,收率30.6％)，为黄色固体。
MS(ESI):m/z＝505.4[M+H] +.
1H NMR(400MHz,CD 3OD)δ7.69(d,J＝9.8Hz,1H),7.64(s,1H),7.45-7.38(m,2H),7.23(d,J＝16.7Hz,1H),7.13-7.05(m,2H),7.04–6.95(m,3H),6.95-6.88(m,1H),6.83(d,J＝9.8Hz,1H),5.54–5.37(m,2H),4.27–3.99(m,3H),3.26-3.20(m,3H),3.08–2.99(m,3H),2.97–2.73(m,2H),2.30–2.12(m,1H).
6-(((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)-3-((Z)-4-(哌嗪-1-基)苯乙烯基)咪唑[1,2-b]哒嗪
Figure PCTCN2020129913-appb-000075
采用类似于实施例15的条件，替换相应的起始原料,得6-(((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)-3-((Z)-4-(哌嗪-1-基)苯乙烯基)咪唑[1,2-b]哒嗪
MS(ESI):m/z＝505.4[M+H] +.
1H NMR(400MHz,CD 3OD)δ8.53(s,1H),7.69(d,J＝9.8Hz,0.5H),7.63(d,J＝10.0Hz,1H),7.43(d,J＝8.8Hz,0.5H),7.30-7.20(m,2H),7.17–6.87(m,5H),6.80(dd,J＝26.1,9.8Hz,1H),6.53(dd,J＝34.5,12.2Hz,1H),5.54–5.33(m,2H),4.26–3.98(m,3H),3.37-3.30(m,3H),3.17-3.10(m,3H),2.95-2.70(m,2H),2.32–2.13(m,1H).
实施例16
6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)-3-((E)-2-(1-(哌啶-4-基)-1H-吡唑-3-基)乙烯基)咪唑并[1,2-b]哒嗪
实施例17
6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)-3-((Z)-2-(1-(哌啶-4-基)-1H-吡唑-3-基)乙烯基)咪唑并[1,2-b]哒嗪
Figure PCTCN2020129913-appb-000076
氯化((1H-吡唑-3-基)甲基)三苯基磷
Figure PCTCN2020129913-appb-000077
向3-(氯甲基)-1H-吡唑盐酸盐(459mg,3mmol)的乙腈(10mL)溶液中加入三苯基膦(865mg,3.3mmol)和三乙胺(606mg,6mmol)，80度反应16小时。反应混合物减压浓缩后用乙醚打浆、真空干燥得到氯化((1H-吡唑-3-基)甲基)三苯基磷(1.02g,产率94％)，为棕色固体。
MS(ESI):m/z＝343.0[M+H] +.
3-((E)-2-(1H-吡唑-3-基)乙烯基)-6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪
3-((Z)-2-(1H-吡唑-3-基)乙烯基)-6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪
Figure PCTCN2020129913-appb-000078
-78度下向氩气保护的氯化((1H-吡唑-3-基)甲基)三苯基磷(189mg,0.5mmol)的四氢呋喃(5mL)溶液中滴加正丁基锂(0.2mL,0.5mmol)，在同样的温度下反应0.5小时，向反应液中加入6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-甲醛 (87mg,0.25mmol)，-78度反应半小时后，升至室温继续反应16小时。加水(5mL)淬灭反应，然后加入乙酸乙酯(10mL)。有机相经水洗、盐洗、无水硫酸钠干燥、过滤、浓缩，残留物通过正相柱层析(甲醇:二氯甲烷＝1:15)纯化，得到3-((E)-2-(1H-吡唑-3-基)乙烯基)-6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪和3-((Z)-2-(1H-吡唑-3-基)乙烯基)-6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪的混合物(60mg,产率58％),为黄色色固体。
MS(ESI):m/z＝411.1[M+H] +.
叔-丁基4-(3-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)-1H-吡唑-1-基)哌啶-1-羧酸酯
叔-丁基4-(3-((Z)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)-1H-吡唑-1-基)哌啶-1-羧酸酯
Figure PCTCN2020129913-appb-000079
室温下向氢化钠(12mg,0.292mmol)的四氢呋喃(5mL)悬浮液中加入上一步的混合产物，反应液在70度搅拌6小时。加入水淬灭反应，然后用乙酸乙酯萃取。有机相用水洗、盐洗、硫酸钠干燥。粗产品通过正相柱层析(甲醇:二氯甲烷＝1:16)纯化，得到包含反式和顺式的混合产物(65mg,产率74.6％)，为黄色油状物。
MS(ESI):m/z＝594.2[M+H] +
6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)-3-((E)-2-(1-(哌啶-4-基)-1H-吡唑-3-基)乙烯基)咪唑并[1,2-b]哒嗪
6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)-3-((Z)-2-(1-(哌啶-4-基)-1H-吡唑-3-基)乙烯基)咪唑并[1,2-b]哒嗪
Figure PCTCN2020129913-appb-000080
将上一步得到的产品(65mg,0.109mmol)溶于二氯甲烷(1.5mL)中，加入三氟乙酸(0.5mL)，室温搅拌1小时。反应完毕后，溶剂经旋蒸移除，粗产品经Prep-HPLC分离(乙腈/水(含0.1％NH 4HCO 3)梯度冲洗)得到白色固体6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)-3-((E)-2-(1-(哌啶-4-基)-1H-吡唑-3-基)乙烯基)咪唑并[1,2-b]哒嗪(15 mg,产率27.5％)和白色固体6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)-3-((Z)-2-(1-(哌啶-4-基)-1H-吡唑-3-基)乙烯基)咪唑并[1,2-b]哒嗪(12mg,产率22％)。
6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)-3-((E)-2-(1-(哌啶-4-基)-1H-吡唑-3-基)乙烯基)咪唑并[1,2-b]哒嗪
MS(ESI):m/z＝494.1[M+H] +.
1H NMR(400MHz,CD 3OD)δ7.74–7.59(m,3H),7.36(d,J＝16.7Hz,1H),7.21–7.02(m,3H),7.01–6.87(m,1H),6.82(d,J＝9.8Hz,1H),6.56(d,J＝2.4Hz,1H),5.55–5.35(m,2H),4.43–4.29(m,1H),4.17(dd,J＝25.5,13.1Hz,2H),3.32(s,1H),2.99–2.80(m,3H),2.39–1.86(m,6H).
6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)-3-((Z)-2-(1-(哌啶-4-基)-1H-吡唑-3-基)乙烯基)咪唑并[1,2-b]哒嗪
MS(ESI):m/z＝494.1[M+H] +.
1H NMR(400MHz,CD 3OD)δ8.47(s,1H),8.39(s,1H),7.70(d,J＝9.7Hz,1H),7.65(d,J＝2.4Hz,1H),7.18–7.06(m,2H),7.01–6.90(m,1H),6.84(d,J＝9.8Hz,1H),6.66(d,J＝13.0Hz,1H),6.44(d,J＝13.0Hz,1H),6.34(d,J＝2.3Hz,1H),5.55–5.36(m,2H),4.63–4.46(m,1H),4.22–4.00(m,2H),3.53(d,J＝13.3Hz,2H),3.25–3.12(m,2H),2.92–2.77(m,1H),2.41–2.11(m,5H).
实施例18
(R)-1-(2-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)嘧啶-5-基)吡咯烷-3-醇
Figure PCTCN2020129913-appb-000081
向二氧六环(3mL)溶剂中加入3-((E)-2-(5-溴嘧啶-2-基)乙烯基)-6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪(100mg,0.2mmol)，(R)-吡咯烷-3-醇(87mg,1mmol),三(二亚苄基丙酮)二钯(18mg,0.02mmol)，4,5-双二苯基膦-9,9-二甲基氧杂蒽(23mg,0.04mmol)和碳酸铯(130mg,0.4mmol)，氩气保护下100度反应16小时。反应液冷却至室温后加入乙酸乙酯稀释，有机相经水洗、盐洗、硫酸钠干燥，所得粗产物经Prep-HPLC分离(乙腈/水(含0.1％NH 4HCO 3)梯度冲洗)得到(R)-1-(2-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)嘧啶-5-基)吡咯烷-3-醇(38mg,产率37.5％)，为白色固体。
MS(ESI):m/z＝508.4[M+H] +.
1H NMR(400MHz,CD3OD)δ8.12(s,2H),7.74(d,J＝17.7Hz,2H),7.67(d,J＝9.8Hz,1H),7.52(d,J＝16.3Hz,1H),7.17–7.05(m,2H),6.93(dd,J＝10.3,6.2Hz,1H),6.74(d,J＝10.0Hz,1H),5.57–5.38(m,2H),4.57(s,1H),4.31–4.08(m,2H),3.62–3.43(m,3H),3.33(s,1H),3.00–2.83(m,1H),2.38–1.97(m,4H).
实施例19
1-(5-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)吡嗪-2-基)哌嗪-2-酮
Figure PCTCN2020129913-appb-000082
叔-丁基4-(5-氯吡嗪-2-基)-3-羰基哌嗪-1-羧酸酯
Figure PCTCN2020129913-appb-000083
氩气保护下，向2-溴-5-氯吡嗪(772mg,4mmol)，叔-丁基3-羰基哌嗪-1-羧酸酯(960mg,4.8mmol)和磷酸钾(848mg,8mmol)的二氧六环(10mL)溶剂中加入碘化亚铜(152mg,0.8mmol)和N1,N2-二甲基乙烷-1,2-二胺(141mg,1.6mmol)，100度反应2小时后，加入适量水淬灭，用乙酸乙酯萃取。有机相经水洗、盐洗后浓缩，残留物经正想柱层析纯化(乙酸乙酯：石油醚＝1:2)得到叔-丁基4-(5-氯吡嗪-2-基)-3-羰基哌嗪-1-羧酸酯(620mg,产率49.5％)，为白色固体。
MS(ESI):m/z＝313.0[M+H] +.
叔-丁基3-羰基-4-(5-乙烯基吡嗪-2-基)哌嗪-1-羧酸酯
Figure PCTCN2020129913-appb-000084
向二氧六环(10mL)和水(10mL)的混合溶剂中加入叔-丁基4-(5-氯吡嗪-2-基)-3-羰基哌嗪-1-羧酸酯(620mg,1.98mmol),4,4,5,5-四甲基-2-乙烯基-1,3,2-二噁硼戊环(366mg,2.376mmol)，[1,1'-双(二苯基膦基)二茂铁]二氯化钯(146mg,0.2mmol)和碳酸钾(546mg,3.96mmol)，氩气保护下100度反应2小时。反应液冷却至室温后加入乙酸乙酯稀释，有机相经水洗、盐洗后浓缩，残留物经正相柱层析纯化(乙酸乙酯：石油醚＝1:2)得到叔-丁基3-羰基-4-(5-乙烯基吡嗪-2-基)哌嗪-1-羧酸酯(550mg,产率44.1％)，为黄色油状物。
MS(ESI):m/z＝305.1[M+H] +.
叔-丁基4-(5-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)吡嗪-2-基)-3-羰基哌嗪-1-羧酸酯
Figure PCTCN2020129913-appb-000085
氩气保护下，向叔-丁基3-羰基-4-(5-乙烯基吡嗪-2-基)哌嗪-1-羧酸酯(91mg,0.3mmol)和3-溴-6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪(119mg,0.3mmol)的N,N-二甲基甲酰胺(3mL)溶液中加入醋酸钯(7mg,0.03mmol),三苯基膦(16mg,0.06mmol)和N,N-二异丙基乙胺(116mg,0.9mmol)，在微波反应器中120度反应3小时。向反应液中加入乙酸乙酯稀释，有机相经水洗、盐洗后浓缩，残留物经正想柱层析纯化(甲醇：二氯甲烷＝1:10)得到叔-丁基4-(5-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)吡嗪-2-基)-3-羰基哌嗪-1-羧酸酯(90mg,产率48.3％)，为黄色油状物。
MS(ESI):m/z＝621.1[M+H] +.
1-(5-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)吡嗪-2-基)哌嗪-2-酮
Figure PCTCN2020129913-appb-000086
向叔-丁基4-(5-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)吡嗪-2-基)-3-羰基哌嗪-1-羧酸酯(90mg,0.145mmol)的二氯甲烷(1.5mL)溶液中加入三氟乙酸(0.3mL)。混合物室温反应1小时后浓缩除去溶剂，加入N,N-二甲基甲酰胺溶液(1mL)，用碳酸氢钠水溶液调节至碱性，所得粗产物经Prep-HPLC分离(乙腈/水(含0.1％NH 4HCO 3)梯度冲洗)得到1-(5-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)吡嗪-2-基)哌嗪-2-酮(48mg,产率63.4％)，为黄色固体。
MS(ESI):m/z＝521.0[M+H] +.
1H NMR(400MHz,DMSO-d 6)δ9.20(s,1H),8.51(s,1H),7.93(d,J＝9.8Hz,1H),7.89(s,1H),7.76(d,J＝16.1Hz,1H),7.51(d,J＝16.0Hz,1H),7.31–7.18(m,2H),7.07(dd,J＝10.3,6.4Hz,1H),6.91(d,J＝9.6Hz,1H),5.66–5.44(m,2H),4.19(ddd,J＝37.1,19.2,7.8Hz,2H),3.94–3.80(m,2H),3.52(s,2H),3.07(t,J＝5.4Hz,2H),2.95–2.78(m, 2H),2.25(ddd,J＝41.4,16.9,6.8Hz,1H).
实施例20
4-(2-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)嘧啶-5-基)哌嗪-2-酮
Figure PCTCN2020129913-appb-000087
采用类似于实施例3的条件，替换相应的起始原料,得4-(2-((E)-2-(6-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)嘧啶-5-基)哌嗪-2-酮(19mg,收率56％)，为黄色固体。
MS(ESI):m/z＝521.0[M+H] +.
1H NMR(400MHz,CD 3OD)δ8.46(s,2H),7.85(d,J＝16.2Hz,1H),7.75(s,1H),7.69(d,J＝9.8Hz,1H),7.53(d,J＝16.2Hz,1H),7.12(ddd,J＝13.5,9.3,4.3Hz,2H),6.93(dt,J＝12.0,3.4Hz,1H),6.78(d,J＝9.8Hz,1H),5.57–5.38(m,2H),4.30–4.08(m,2H),3.99(s,2H),3.62(dd,J＝6.4,4.2Hz,2H),3.50(dd,J＝6.3,4.2Hz,2H),2.99–2.84(m,1H),2.37–2.16(m,1H).
实施例21
(R,E)-4-(3-(2-(6-(2-(2,5-二氟苯基)吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)-1,2,4-噁二唑-5-基)哌嗪-2-酮
Figure PCTCN2020129913-appb-000088
(R,E)-3-(6-(2-(2,5-二氟苯基)吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)丙烯腈
Figure PCTCN2020129913-appb-000089
向氰甲基磷酸二乙酯(373mg,2.10mmol)的四氢呋喃(8mL)溶液中0℃加入60％氢化钠(84mg,2.10mmol)。反应液室温搅拌1小时后，0℃缓慢滴加(R)-6-(2-(2,5-二氟苯基)吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-甲醛(230mg,0.70mmol)的四氢呋喃(2mL)溶液,缓慢升至室温并搅拌16小时。加水(50mL)稀释,用二氯甲烷萃取(50mL*1)。合并有机相干燥,浓缩，残渣通后加入水(0.1ml)淬灭,浓缩，残渣通过正相柱层析(二氯甲烷:甲醇＝20:1)纯化，得到标题化合物(R,E)-3-(6-(2-(2,5-二氟苯基)吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)丙烯腈(284mg粗品)，为无色液体。
MS(ESI):m/z＝352.1[M+H] +.
(1E,2E)-3-(6-((R)-2-(2,5-二氟苯基)吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)-N'-羟基丙烯酰基脒
Figure PCTCN2020129913-appb-000090
向(R,E)-3-(6-(2-(2,5-二氟苯基)吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)丙烯腈(284mg,粗品)，盐酸羟胺(243mg，3.5mmol)的乙醇(10mL)和水(1mL)混合溶液中三乙胺(850mg，8.4mmol)。反应液闷罐80℃搅拌7小时后，浓缩，残渣通过正相柱层析(二氯甲烷:甲醇＝20:1)纯化，得到标题化合物(1E,2E)-3-(6-((R)-2-(2,5-二氟苯基)吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)-N'-羟基丙烯酰基脒(230mg,收率85.5％)，为黄色固体。
MS(ESI):m/z＝385.1[M+H] +
(R,E)-3-(2-(6-(2-(2,5-二氟苯基)吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)-5-(三氯甲基)-1,2,4-噁二唑
Figure PCTCN2020129913-appb-000091
向(1E,2E)-3-(6-((R)-2-(2,5-二氟苯基)吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)-N'-羟基丙 烯酰基脒(320mg,0.832mmol)，吡啶(593mg,7.49mmol)的甲苯(15mL)溶液中0℃加入三光气(2.29g,7.49mmol)。反应液室温搅拌16小时后，加入饱和碳酸氢钠水溶液(100mL),用乙酸乙酯萃取(100mL*1).有机相用水(100mL*1)洗，饱和食盐水(100mL*1)洗，干燥，过滤，浓缩，残渣通过正相柱层析(乙酸乙酯)纯化，得到标题化合物(R,E)-3-(2-(6-(2-(2,5-二氟苯基)吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)-5-(三氯甲基)-1,2,4-噁二唑(169mg,收率39.7％)，为黄色固体。
MS(ESI):m/z＝510.9[M+H] +.
叔-丁基(R,E)-(2-((3-(2-(6-(2-(2,5-二氟苯基)吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)-1,2,4-噁二唑-5-基)氨基)乙基)氨基甲酸酯
Figure PCTCN2020129913-appb-000092
向(R,E)-3-(2-(6-(2-(2,5-二氟苯基)吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)-5-(三氯甲基)-1,2,4-噁二唑(140mg,0.274mmol)的二甲基亚砜(7mL)的溶液中加入N-叔丁氧羰基-1,2-乙二胺(432mg，2.74mmol)。反应液室温搅拌16小时后加入二氯甲烷(50mL)稀释，用水(100mL*1)洗，干燥,过滤，浓缩，残渣通过正相柱层析(二氯甲烷:甲醇＝10:1)纯化，得到标题化合物叔-丁基(R,E)-(2-((3-(2-(6-(2-(2,5-二氟苯基)吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)-1,2,4-噁二唑-5-基)氨基)乙基)氨基甲酸酯(100mg,收率66.0％)，为黄色固体。
MS(ESI):m/z＝553.0[M+H] +
(R,E)-N1-(3-(2-(6-(2-(2,5-二氟苯基)吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)-1,2,4-噁二唑-5-基)乙烷-1,2-二胺
Figure PCTCN2020129913-appb-000093
向叔-丁基(R,E)-(2-((3-(2-(6-(2-(2,5-二氟苯基)吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)-1,2,4-噁二唑-5-基)氨基)乙基)氨基甲酸酯(90mg,0.181mmol)的甲醇(0.5mL)溶 液中0℃加入4N盐酸二氧六环(10mL)。反应室温搅拌1小时后浓缩，得到标题化合物(R,E)-N1-(3-(2-(6-(2-(2,5-二氟苯基)吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)-1,2,4-噁二唑-5-基)乙烷-1,2-二胺(170mg粗品)，为黄色固体。
MS(ESI):m/z＝453.1[M+H] +.
(R,E)-2-氯-N-(2-((3-(2-(6-(2-(2,5-二氟苯基)吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)-1,2,4-噁二唑-5-基)氨基)乙基)乙酰胺
Figure PCTCN2020129913-appb-000094
向(R,E)-N1-(3-(2-(6-(2-(2,5-二氟苯基)吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)-1,2,4-噁二唑-5-基)乙烷-1,2-二胺(170mg,0.181mmol)，N,N-二异丙基乙胺(170mg,0.181mmol)，的二氯甲烷(10mL)和N,N-二甲基甲酰胺(2mL)的溶液中0℃滴加氯乙酰氯(20mg，0.181mmol)。反应液0℃搅拌0.5小时后加入二氯甲烷(30mL)稀释，用水(30mL*1)洗，干燥,过滤，浓缩，残渣通过正相柱层析(二氯甲烷:甲醇＝10:1)纯化，得到标题化合物(R,E)-2-氯-N-(2-((3-(2-(6-(2-(2,5-二氟苯基)吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)-1,2,4-噁二唑-5-基)氨基)乙基)乙酰胺(80mg,收率83.4％)，为棕色油状物。
MS(ESI):m/z＝529.0[M+H] +.
(R,E)-4-(3-(2-(6-(2-(2,5-二氟苯基)吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)-1,2,4-噁二唑-5-基)哌嗪-2-酮
Figure PCTCN2020129913-appb-000095
向(R,E)-2-氯-N-(2-((3-(2-(6-(2-(2,5-二氟苯基)吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)-1,2,4-噁二唑-5-基)氨基)乙基)乙酰胺(80mg,0.151mmol),N,N-二异丙基乙胺(390mg,0.151mmol的N,N-二甲基甲酰胺(10mL)溶液中加入碘化钾(226mg,1.51mmol)。反应液90℃搅拌16小时,后浓缩，残渣通残渣经Prep-HPLC分离(乙腈/水(含0.1％NH 4HCO 3)梯度冲洗)得到标题化合物得到标题化合物(R,E)-4-(3-(2-(6-(2-(2,5-二氟苯基)吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙烯基)-1,2,4-噁二唑-5-基)哌嗪-2-酮(7mg,收率9.4％)，为立白色固体。
MS(ESI):m/z＝493.1[M+H] +.
1H NMR(400MHz,DMSO-d 6)δ8.24(s,1H),7.91–7.80(m,2H),7.53(d,J＝16.0Hz,1H),7.26-7.20(m,1H),7.18–7.00(m,2H),6.98-6.95(m,1H),6.92-6.72(m,1H),5.31(d,J＝6.9Hz,1H),4.08(s,2H),4.01–3.91(m,1H),3.79–3.66(m,2H),3.61-3.54(m,1H),3.35-3.30(m,2H),2.45-2.40(m,1H),2.10-1.90(m,2H),1.92-1.82(m,1H).
生物测试例1 TRKA，TRKB，TRKC激酶体外活性测试
实验材料
重组人源TRKA，TRKB，TRKC蛋白购自Carna Biosciences。HTRF kinEASE TK kit购自CisbioBioassays。使用BioTek酶标仪Synergy Neo 2读板。
实验方法
将测试化合物进行3倍浓度梯度稀释，终浓度为1μM到0.05nM 10个浓度，每个浓度两个复孔；DMSO在检测反应中的含量为1％。
TRKA酶反应：
0.2ng/μl TRKA蛋白激酶，1μM TK Substrate-biotin多肽底物，14.68μM ATP，1×enzymatic buffer，5mM MgCl 2，1mM DTT。检测板为White Proxiplate384-Plus plate(PerkinElmer)，室温反应40分钟，反应体系为10μl。
TRKB酶反应：
0.037ng/μl TRKB蛋白激酶，1μM TK Substrate-biotin多肽底物，4.77μM ATP，1×enzymatic buffer，5mM MgCl 2，1mMMnCl 2，1mM DTT。检测板为White Proxiplate 384-Plus plate(PerkinElmer)，室温反应50分钟，反应体系为10μl。
TRKC酶反应：
0.037ng/μl TRKC蛋白激酶，1μM TK Substrate-biotin多肽底物，25.64μM ATP，1×enzymatic buffer，5mM MgCl 2，1mM DTT。检测板为White Proxiplate 384-Plus plate(PerkinElmer)，室温反应40分钟，反应体系为10μl。
反应检测：
加入10μl的检测试剂至反应板中，含终浓度0.125μM SA-XL665和5μl1×TK-Antibody，室温孵育过夜，Synergy Neo 2读板。
数据分析
将665/620Ratio数值通过下列公式将读数转化成抑制率(％)＝(1-Ratio test/Ratio max)×100％。Ratio max为不含检测化合物的阳性对照，Ratio test为不同化合物各浓度的检测值。4参数曲线拟合测得IC50(nM)数据，具体见表1。
表1
Compound TRKA(nm) TRKB(nm) TRKC(nm)
实施例1 <10 <10 <10
实施例4 <10 <10 <10
实施例5 <10 <100 <100
实施例6 <10 <10 <10
实施例7 <10 <10 <10
实施例8 <10 <10 <10
实施例14 <10 <10 <10
实施例15 <10 <10 <10
实施例16 <10 <10 <10
实施例17 <10 <10 <10
实施例18 <10 <10 <10
生物测试例2:KM12-LUC细胞增殖实验
含有TPM3-NTRK1融合基因的的人结肠癌细胞株KM12-LUC(LUC,稳定表达Luciferace)用于待测化合物细胞学水平药效评估的模型。KM12-LUC细胞中的TRK融合基因使其不依赖于胞外生长因子的刺激，可以持续自发激活并激活其下游信号通路MAPK-ERK、PI3K-AKT等与细胞增殖密切相关的信号通路。因此，在KM12-LUC细胞中抑制TRK活性可显著抑制细胞的增殖。方法如下：第一天，在384孔板中接种细胞，2000细胞/孔；第二天加不同浓度的待测化合物；第五天，加CellTiter-Glo(Promega)检测细胞活性，计算细胞72小时增殖抑制率。用prism5来进行统计分析并得出待测化合物的IC 50值。
结果显示，本发明化合物能够有效的抑制KM12-LUC细胞的增殖,具体见表2
表2
Figure PCTCN2020129913-appb-000096
生物测试例3突变的TRKA(G595R),TRKA(G667C)and TRKC(G623R)激酶体外活性测试
实验材料
重组人源TRKA(G595R)，TRKA(G667C)，TRKC(G623R)蛋白购自SignalChem。HTRF kinEASE TK kit购自CisbioBioassays。使用BioTek酶标仪Synergy Neo 2读板。
实验方法
将测试化合物进行4倍浓度梯度稀释，终浓度为1μM到0.004nM 10个浓度，每个浓度两个复孔；DMSO在检测反应中的含量为1％。
TRKA(G595R)酶反应：
0.12ng/μlTRKA(G595R)蛋白激酶，1μM TK Substrate-biotin多肽底物，4.5μM ATP，1×enzymatic buffer，5mM MgCl 2，1mM DTT。检测板为White Proxiplate384-Plus plate(PerkinElmer)，室温反应30分钟，反应体系为10μl。
TRKA(G667C)酶反应：
0.026ng/μlTRKA(G667C)蛋白激酶，1μM TK Substrate-biotin多肽底物，5.5μM ATP，1×enzymatic buffer，5mM MgCl 2，1mM DTT。检测板为White Proxiplate 384-Plus plate(PerkinElmer)，室温反应30分钟，反应体系为10μl。
TRKC(G623R)酶反应：
1.0ng/μlTRKC(G623R)蛋白激酶，1μM TK Substrate-biotin多肽底物，62.9μM ATP，1×enzymatic buffer，5mM MgCl 2，1mM DTT。检测板为White Proxiplate 384-Plus plate(PerkinElmer)，室温反应50分钟，反应体系为10μl。
反应检测：
加入10μl的检测试剂至反应板中，含终浓度0.125μM SA-XL665和5μl1×TK-Antibody，室温孵育过夜，Synergy Neo 2读板。
数据分析
将665/620Ratio数值减去不含酶的阴性对照孔数值后通过下列公式将读数转化成抑制率(％)＝(1-Ratio test/Ratio max)×100％。Ratio max为不含检测化合物的阳性对照，Ratio test为不同化合物各浓度的检测值。4参数曲线拟合测得IC50(nM)数据，具体见表3。
表3
Figure PCTCN2020129913-appb-000097
生物测试例4：用elisa方法检测细胞学水平TRK激酶活性
通过质粒转染构建稳定表达ΔTRKA或ΔTRKA(G595R)的NIH-3T3细胞株。
第一天接种细胞于96孔细胞培养板，10000细胞/孔于培养基中(DMEM+10％BS)。第二天加不同浓度的待测化合物处理细胞2个小时后将细胞培养板置于冰上；去掉上清，用预冷的PBS润洗一次。用含有蛋白酶和磷酸酶抑制剂的NP40裂解液裂解细胞，并将其转移至抗体预包被的板条中，封板并4度过夜孵育。剩余步骤参照elisa试剂盒中提供的方法进行(例如R&DDYC2578-2中所描述)，具体见表4。
结果显示，本发明化合物能够在细胞学水平有效的抑制ΔTRKA/NIH-3T3细胞或ΔTRKA(G595R)/NIH-3T3细胞TRKA的磷酸化水平。
表2
Compound ΔTRKA(G595R)IC50(nm)
实施例1 <10
实施例2 <10
实施例8 <50
实施例10 <10
实施例11 <10
生物测试例5:本发明中小分子抑制剂治疗肿瘤体内药效实验
建立皮下移植肿瘤的小鼠模型，以检查这些化合物对肿瘤生长的体内抑制效果。方法如下：
将ΔTRKA(G595R)/3T3细胞(5×10 6)皮下注射到小鼠的背侧区域。通过用卡尺测量直径来监测肿瘤体积，并通过下式计算：长度×(宽度2)/2。当肿瘤大小在150和200mm2之间时，随机选择小鼠以接受空白制剂，3mg/kg或30mg/kg/剂量的待测化合物。通过口服给药施用待测化合物，持续7天，每天监测肿瘤生长情况及体重。最后一次给药后2小时，收集肿瘤组织和血液。绘制肿瘤生长曲线，检测肿瘤及血液样本中待测化合物浓度，检测肿瘤样本中TRKA磷酸化水平及其下游信号分子如ERK或AKT磷酸化水平。结果如附图1和2中所示，图1显示了实施例1化合物给药后肿瘤样本中TRKA磷酸化水平，结果显示，本发明化合物给药后能够有效抑制肿瘤样本中TRKA磷酸化水平。图2显示了实施例1化合物给药后小鼠的肿瘤体积变化，结果显示，在本发明化合物给药后，肿瘤生长被明显抑制。
在本发明提及的所有文献都在本申请中引用作为参考，就如同每一篇文献被单独引用作为参考那样。此外应理解，在阅读了本发明的上述讲授内容之后，本领域技术人员可以对本发明作各种改动或修改，这些等价形式同样落于本申请所附权利要求书所限定的范围。

Claims (10)

  1. 一种式I所示的化合物或其立体异构体或外消旋体或其药学上可接受的盐：
    Figure PCTCN2020129913-appb-100001
    其中，
    X 4和X 5各自独立地为N或C；
    L 1选自下组：-NH-、-CH＝CH-、-NH(CHR)-、-NHC(O)NH-、-CH 2-O-、-CH 2-S-、-NHS(O) 2-、-S(O) 2-、-S(O)-；R选自下组：H、C1-C4烷基、卤素；
    L 2选自下组：取代或未取代的C6-C10芳基、取代或未取代的具有1-3个选自N、S和O的杂原子的5-10元杂芳基、取代或未取代的具有1-3个选自N、S和O的杂原子的5-12元杂环基(包括并环、桥环、螺环)；
    或所述的L 1和L 2共同形成选自下组的基团：取代或未取代的10-12元二环含氮杂芳基，或取代或未取代的10-12元二环含氮杂环基；其中，所述的杂芳基或杂环基具有1-3个选自N、S和O的杂原子；
    Rc为取代或未取代的4-6元的杂环基(优选为饱和或不饱和的氮杂环基)、取代或未取代的5-10元杂芳基；其中，所述的杂芳基或杂环基具有1-3个选自N、S和O的杂原子；
    R A为
    Figure PCTCN2020129913-appb-100002
    其中，
    X 1、X 2、X 3各自独立地为CR 6或N；R 6为氢、氘、羟基、卤素、取代或未取代的C1-C6烷基、或取代或未取代的C1-C6烷氧基；
    n为1、2或3；
    各个R 3各自独立地为氢、氘、羟基、卤素、三氟甲基，氰基，氨基，酰胺基，取代或未取代的C1-C6烷基、或取代或未取代的C1-C6烷氧基；
    或者n为2且两个R 3共同形成-O-(CH 2) m-O-；m为1-4的整数；
    R B为取代或未取代的4-7元杂环(所述杂环含有1-3个选自氮原子、氧原子和硫原子的杂原子)；-(CH 2) m1-、-O-(CH 2) m2-O-；其中，m1、m2各自独立地为1-4的整数；
    或者R B为-取代或未取代的-C1-C10亚烷基-X 2-(其中，X 2为NH、O、S或S(O) 2)、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基；除非特别说明，所述的“取代”是指被选自下组的一个或多个(例如2个、3个、4个等)取代基所取代：氘、 卤素、卤代的C1-C6烷基、卤代的C1-C6烷氧基、卤代的C3-C8环烷基、甲基砜基、-S(＝O) 2NH 2、氧代(＝O)、-CN、羟基、-NH 2、羧基、C1-C6酰胺基(-C(＝O)-N(R d) 2或-NH-C(＝O)(R d)，R d为H或C1-C5的烷基)、C1-C6烷基-(C1-C6酰胺基)、
    Figure PCTCN2020129913-appb-100003
    或取代或未取代的选自下组的基团：C1-C6烷基、C1-C6烷氧基、C3-C8环烷基、C1-C6胺基、C6-C10芳基、具有1-3个选自N、S和O的杂原子的5-10元杂芳基、具有1-3个选自N、S和O的杂原子的3-12元杂环基、-(CH 2)-C6-C10芳基、-(CH 2)-(具有1-3个选自N、S和O的杂原子的5-10元杂芳基)，且所述的取代基选自下组：卤素、C1-C6烷基、C1-C6烷氧基、氧代、-CN、-NH 2、-OH、C6-C10芳基、C1-C6胺基、-S(＝O) 2CH 3、-S(＝O) 2NH 2、具有1-3个选自N、S和O的杂原子的5-10元杂芳基；
    虚线表示化学键或无。
  2. 如权利要求1所述的化合物或其立体异构体或外消旋体或其药学上可接受的盐：其特征在于，L 1为-CH＝CH-。
  3. 如权利要求1所述的化合物或其立体异构体或外消旋体或其药学上可接受的盐：其特征在于，R A选自下组：
    Figure PCTCN2020129913-appb-100004
    各式中，X 1、X 2定义同前；
    芳香环上，n为1、2或3；且R 3为氢、氘、羟基、卤素、取代或未取代的C1-C6烷基、或取代或未取代的C1-C6烷氧基；或者n为2且两个R 3共同形成-O-(CH 2) m-O-；m为1-4的整数；
    其它位置的R 3、R 4、R 5各自独立地为氢、氘、羟基、卤素、取代或未取代的C1-C6烷基、或取代或未取代的C1-C6烷氧基。
  4. 如权利要求1所述的化合物或其立体异构体或外消旋体或其药学上可接受的盐：其特征在于，R A为
    Figure PCTCN2020129913-appb-100005
    其中，X 1为CR 6或N；X 2、X 3各自独立地为CR 6；
    n为1、2或3；且R 3为氢、氘、羟基、卤素、取代或未取代的C1-C6烷基、或取代或未取代的C1-C6烷氧基；或者n为2且两个R 3共同形成-O-(CH 2) m-O-；m为1-4的整数。
  5. 如权利要求1所述的化合物或其立体异构体或外消旋体或其药学上可接受的盐：其特征在于，所述的式I化合物具有如下式所示的结构：
    Figure PCTCN2020129913-appb-100006
  6. 如权利要求1所述的化合物或其立体异构体或外消旋体或其药学上可接受的盐：其特征在于，选自下组：
    Figure PCTCN2020129913-appb-100007
    Figure PCTCN2020129913-appb-100008
  7. 一种药物组合物，其包含治疗有效量的权利要求1所述的化合物或其立体异构体或外消旋体或其药学上可接受的盐，以及药学上可接受的赋形剂。
  8. 权利要求1所述的化合物或其立体异构体或外消旋体或其药学上可接受的盐或权利要求7所述的药物组合物的用途，其特征在于，用于预防和治疗与TRK功能异常相关的疾病的药物中的用途。
  9. 一种TRK抑制剂，其特征在于，所述抑制剂包含权利要求1所述的化合物、或其 立体异构体或互变异构体、或其药学上可接受的盐、水合物或溶剂化物。
  10. 如权利要求9所述的TRK抑制剂，其特征在于，所述的抑制剂用于治疗选自下组的疾病：癌症，增生性疾病，疼痛，皮肤病或病症，代谢疾病，肌肉疾病，神经性疾病，自身免疫疾病，皮炎引起的瘙痒，炎症相关疾病，骨相关的疾病。
PCT/CN2020/129913 2019-11-18 2020-11-18 一类蛋白受体激酶抑制剂的制备和应用 WO2021098745A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202080074424.6A CN114641476B (zh) 2019-11-18 2020-11-18 一类蛋白受体激酶抑制剂的制备和应用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201911130029.0 2019-11-18
CN201911130029.0A CN112812118A (zh) 2019-11-18 2019-11-18 一类蛋白受体激酶抑制剂的制备和应用

Publications (1)

Publication Number Publication Date
WO2021098745A1 true WO2021098745A1 (zh) 2021-05-27

Family

ID=75852765

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/129913 WO2021098745A1 (zh) 2019-11-18 2020-11-18 一类蛋白受体激酶抑制剂的制备和应用

Country Status (2)

Country Link
CN (2) CN112812118A (zh)
WO (1) WO2021098745A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114989176A (zh) * 2022-07-08 2022-09-02 深圳市新樾生物科技有限公司 咪唑并哒嗪类衍生物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033941A1 (en) * 2008-09-22 2010-03-25 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
WO2010048314A1 (en) * 2008-10-22 2010-04-29 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637516B2 (en) * 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033941A1 (en) * 2008-09-22 2010-03-25 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
WO2010048314A1 (en) * 2008-10-22 2010-04-29 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114989176A (zh) * 2022-07-08 2022-09-02 深圳市新樾生物科技有限公司 咪唑并哒嗪类衍生物及其应用

Also Published As

Publication number Publication date
CN114641476B (zh) 2023-05-02
CN114641476A (zh) 2022-06-17
CN112812118A (zh) 2021-05-18

Similar Documents

Publication Publication Date Title
EP3712151B1 (en) (s)-1&#39;-(8-((2-amino-3-chloropyridin-4-yl)thio)imidazo[1,2-c]pyrimidin-5-yl)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4&#39;-piperidine]-5-amine as shp2 inhibitor for the treatment of cancer
CN107857755B (zh) 作为trka激酶抑制剂的n-吡咯烷基、n′-吡唑基-脲、硫脲、胍和氰基胍化合物
WO2019158019A1 (zh) 嘧啶并环化合物及其制备方法和应用
WO2021018287A1 (zh) 一种螺芳环化合物、其制备及应用
CN112585139A (zh) 用作t细胞激活剂的萘啶酮化合物
IL311187A (en) Compressed ring compounds
WO2020200158A1 (zh) 用于治疗癌症的氮杂芳环酰胺衍生物
WO2017084640A1 (zh) 一种含氮杂环化合物及其制备方法与在抑制激酶活性中的应用
WO2016173557A1 (zh) 一类具有激酶抑制活性的化合物、制备方法和用途
WO2020098720A1 (zh) 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
CN112457326B (zh) 一类芳香杂环并内酰胺类化合物、制备方法和用途
CN111518100A (zh) 环丙烯并苯并呋喃取代的氮杂芳基化合物及其应用
KR101905295B1 (ko) 나프티리딘디온 유도체
WO2021098745A1 (zh) 一类蛋白受体激酶抑制剂的制备和应用
WO2022152274A1 (zh) Fgfr抑制剂化合物及其用途
CN115485281A (zh) 一种fgfr及其突变抑制剂,其制备方法和应用
TW202216714A (zh) 含氮稠雜環類化合物及其製備方法和應用
WO2020078360A1 (zh) 一类蛋白受体激酶抑制剂的制备和应用
CN111747954B (zh) 吡嗪化合物和其用途
CN111057048A (zh) 一类氨基吡嗪/吡啶类化合物、制备方法和用途
CN115215862A (zh) 嘧啶酮化合物及其用途
CN116096720A (zh) 二氢吡咯并[2,3-d]哒嗪-7-酮衍生物，其制备方法和应用
WO2023078426A1 (zh) 一种化合物、包含其的药物组合物及其应用
WO2023046030A1 (zh) 一种egfr小分子抑制剂、含其的药物组合物及其用途
WO2020200154A1 (zh) 一类噻吩并氮杂环类化合物、制备方法和用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20889939

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20889939

Country of ref document: EP

Kind code of ref document: A1